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ABSTRACT PAGE
Pax5 is an alternatively spliced transcription factor that regulates B cell development, 
activation, and differentiation. Although misexpression of Pax5 is associated with 
malignancies such as lymphomas, research has yet to elucidate the function of specific 
Pax5 isoforms and to further correlate these isoforms with disease or B cell developmental 
stages. Our study hypothesized that in the anterior kidney, blood, and spleen of rainbow 
trout, specific Pax5 isoforms characterize individual B cell populations as a means of 
modulating Pax5 activity. Using flow cytometric analyses with antibodies recognizing the 
Pax5 paired domain, exon 6 domain, and C-terminus, we demonstrate that B cell 
populations differentially express Pax5 isoforms. Additionally, using the developmental 
markers Xbp1-S, EBF, and HCmu, we reveal that Pax5 isoforms lacking a paired domain 
are present at the earliest stages of B cell development. Furthermore, we discover for the 
first time in trout that these early developing B cell populations exist in the secondary 
immune tissues, blood and spleen. With these findings, we propose a model in which the 
stages of B cell development and activation are delineated by combinations of Pax5 
domain expression which we have termed the "Pax5 signature". The identification of Pax5 
signatures with flow cytometry provides a means to assess aberrant molecular expression 
in B cell populations and has important implications for clinical diagnostics.
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Chapter 1. Introduction
The immune system is comprised of a multitude of cells capable of targeting 
foreign pathogens and altered self-cells such as cancer cells [1]. Innate immunity 
functions in both vertebrates and invertebrates to activate inflammatory responses leading 
to pathogen destruction [1]. In contrast, the acquired immune system is highly specific 
and found only in vertebrates. When activated, it operates in conjunction with the innate 
immune system by employing T lymphocytes, B lymphocytes and natural killer cells.
The B lymphocyte, the focus of this study, is the antibody secreting cell of the humoral 
(antibody) response. Through a highly regulated process dependent on transcription 
factor cascades and the microenvironment, B cell progenitors develop into mature B cells 
that express membrane immunoglobulin (IgM). Upon antigen encounter, mature B cells 
activate and differentiate into Ig-secreting plasma cells, which secrete antibody that binds 
antigen with high specificity [1].
The phenotypic pathway of B cell development and activation is well delineated 
and fairly conserved across vertebrates. However, unique evolutionary differences in the 
molecular mechanisms and immune tissue locations o f B cell development exist between 
higher and lower vertebrates. While mammalian B lymphopoiesis occurs in the bone 
marrow, lymphopoiesis in lower vertebrates occurs in alternative primary immune 
tissues. O f particular interest are the teleosts which lack bone marrow but instead 
maintain lymphopoiesis in the anterior kidney and launch an acquired immune response 
comparable to that o f their mammalian counterparts [2-4]. The importance of both
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similarities and differences between these two groups will be emphasized and explored 
throughout this chapter.
In addition to cross-species comparisons, the molecular mechanisms determining 
B cell differentiation, particularly the B cell specific factors, require further examination. 
The master regulator o f B cell development is the paired domain transcription factor Pax5 
[5-7]. Pax5 is translated from an alternatively spliced mRNA transcript and is necessary 
for the maintenance of the B cell phenotype [8, 9]. While the role of Pax5 in B cell 
development is conserved, researchers have yet to elucidate the function and expression 
of multiple Pax5 isoforms across immune tissues and species. Identifying the roles of 
individual Pax5 isoforms in B cell development may have important clinical implications, 
as the misexpression of Pax5 isoforms correlates with erroneous B cell proliferation and 
malignancy [10-12]. This chapter will present the current paradigms in B cell 
development and Pax5 alternative splicing, and will highlight important unanswered 
questions linking these mechanisms.
1. B Cell Development
B cell development is a highly regulated, sequential process dependent on the 
microenvironment. Transcription factors, which are DNA-binding proteins, function to 
both activate genes guiding B lymphopoiesis and to suppress genes driving alternative 
cell fates. Cytokines and their receptors also enrich the microenvironment of primary and 
secondary immune tissues and promote the acquisition o f B cell competency (the ability 
of a cell to follow a particular cell lineage). In fact, each stage o f B cell development
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(Figure 1.1) is defined by distinct expression patterns of molecular markers, including 
transcription factors (reviewed in [13]), cytokine receptors, and Ig heavy (H) and light 
(L) chain gene rearrangements. As B cell progenitors progress through the developmental 
stages marked by these molecular patterns, they gradually lose their alternative lineage 
potential until finally acquiring a mature B cell phenotype.
1.1 Hematopoiesis and Common Lymphocyte Progenitors (CLPs)
Hematopoiesis is the process by which pluripotent hematopoietic stem cells either 
self-renew or acquire a progenitor fate capable of producing all immune cell types. In 
most vertebrates, hematopoietic tissues arise from the ventral mesoderm during fetal 
development [14]. During fetal development, the spleen functions as the primary 
hematopoietic site. At birth, mammalian hematopoiesis primarily occurs in the bone 
marrow and continues there throughout adulthood. While bone marrow serves as the 
primary immune tissue in mammals, other tissues, such as dorsal aorta and anterior 
kidney, serve as a site for hematopoiesis in lower vertebrates such as amphibians, 
chickens and teleosts (reviewed in [15]).
The rainbow trout anterior kidney (defined in [2, 16]) functions as the primary 
immune organ and site of hematopoiesis.. These findings were primarily confirmed by 
antigen inhibition assays in which anterior kidney cells had reduced antigen recognition 
capabilities when compared to spleen cells. The results agreed with findings observed in 
murine bone marrow and spleen [4]. In a further parallel, both the anterior kidney of 
teleosts and the bone marrow of mammals house the adventitial, endothelial, and reticular
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cells [17]. The anterior kidney also contains progenitor cells characterized by conserved 
early molecular markers, such as early B cell factor (EBF), recombination activating gene 
(RAG)-1,-2, and Ikaros [18-20]. Although murine and human hematopoietic cells are 
typically identified and defined by the antigenic surface marker CD34 (previously My- 
10), an equivalent cell surface marker for trout hematopoietic cells has yet to be 
identified [21, 22].
In all vertebrates, the pluripotent progenitor cells produced by hematopoiesis have the 
potential to differentiate into all blood cell lineages, but they are developmentally 
restricted to specific lineages by the expression of hormones and cytokines in the stroma 
of hematopoietic tissues. Erythropoietin, for example, restricts cells to erythrocyte fates 
while cytokines interleukin (IL)- 15 and IL-6 restrict cells to natural killer (NK) cell and 
granulocyte lineages respectively (reviewed in [23]). The lymphoid lineage, particularly 
B-lymphocytes, requires exposure to IL-7 [24, 25]. Cells driven toward NK, T- and B- 
lymphocyte fates are collectively known as the common lymphocyte progenitors (CLP).
Common lymphocyte progenitors biased towards the B cell fate are characterized 
by expression of the transcription factors Ikaros and EBF [13, 18, 26]. Ikaros expression 
occurs prior to the activation of B cell-specific genes and is required for lymphoid fate in 
both teleosts and mammals [18, 27]. Mice homozygous deficient for Ikaros lack NK, T-, 
and B-lymphocytes, a finding that demonstrates Ikaros is necessary as a lymphoid 
progenitor regulator [18, 28]. Similar to knock-down experiments for Ikaros, knockdown 
o f EBF results in reduction of lymphoid fates and an increase in myeloid-derived fates. 
Additionally, ectopic expression of EBF directs pluripotent stem cells towards B cell
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fates [29]. While Ikaros functions as a CLP regulator, EBF has a more specific role in B 
cell commitment as it regulates, and is regulated by, Pax5 [29] later in development.
Common lymphocyte progenitors are additionally defined by their level of Ig 
gene rearrangements. RAG1 locus activation occurs in early multipotent progenitor cells 
prior to B cell gene expression [30]. Concurrently, these CLP cells begin expression of 
terminal deoxyncleotidyl transferase (TdT) which is necessary for antigen receptor 
diversity [30, 31]. Prior to differentiation to non-lymphoid fates, CLPs begin to produce 
more Dh-Jh (diversity and joining gene segments) rearrangements [23], but are not 
necessarily committed to the B cell fate [30].
Recently, populations o f early developing B cells including common lymphocyte 
progenitors have been compared using trout and murine primary immune tissues. Using 
flow cytometric analysis and antigenic markers of RAG1 and EBF, Zwollo et al. [32] 
demonstrated that similar early B cell populations exist in both murine bone marrow and 
trout anterior kidney. In addition to expressing these early progenitor cell molecular 
markers, these cell populations were of similar large size (i.e. high in forward light 
scatter- FSC), further emphasizing the evolutionary parallels in mammals and teleosts.
1.2 Pro-B -M ature B Cell Development
As with CLPs, the more differentiated stages o f B cell development (Figure 1.1) 
may be identified by molecular changes in cell surface markers, transcription factors, and 
Ig rearrangements. Pro-B cells differ from CLPs since they are restricted to the B cell fate 
and can no longer produce T cells. In addition, murine pro-B cells are defined by cell
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surface markers B220 and CD43 [33-35]. Both murine and teleost pro-B cells are marked 
by continued expression of EBF and RAG1 with the new expression of Pax5 [32], Pax5 
is the master regulator of B cell commitment and development; Pax5-/- cells arrest at the 
pro-B stage [7, 36], Murine and teleost pro-B cells are also characterized by 
rearrangement of the DJ gene segments at both IgH loci [37, 38].
After the initial heavy chain rearrangement in pro-B cells, cells enter the pre-B 
stages o f development. The pre-B stages are divided into two phases: pre-BI and pre-BII 
(includes large pre-BII and small pre-BII). During pre-BI, EBF and mammalian CD43 
expression decline and the primary immune cells begin expressing heavy chain (HC) mu 
[32, 39-41]. Assembly of the pre-B cell antigen receptor (preBCR) begins as the 
surrogate light chain (LC) forms from the Iga/IgP subunits [23, 36, 38, 42]. Cells then 
undergo positive selection for the preBCR and progress to the pre-BII stage.
In the pre-BII stage, pre-BII cells no longer express either EBF or RAG1 [32].
The variable (V) gene segment recombines to the DJ gene segment and the locus 
undergoes VDJ chain rearrangements [37]. During this stage, cells become smaller, 
shifting from the larger pre-BII cell morphology to smaller pre-BII cell morphology, as 
evidenced through the FSC of flow cytometric analyses [32]. Remarkably, the relative 
frequency of the small, late developing B cell populations (including small pre-BII, 
immature and mature B cells) is well conserved between mouse bone marrow cells and 
trout anterior kidney cells; approximately 1% of bone marrow and anterior kidney cells 
are in the late developing stages.
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The end of pre-BII development and beginning o f the immature B phase is 
characterized by LC gene rearrangement [37]. The immature B cell is the first of the B 
cell lineage to express surface IgM (reviewed in [43]). In mice, immature B cells will 
migrate from the bone marrow to the surrounding lymph nodes, upregulating mature B 
cell genes as they travel [44]. In teleosts such as trout, research suggests migration occurs 
from anterior kidney to either the posterior kidney or the spleen [2]. Once inside the 
secondary immune tissues, B cells will mature, continue to express functional membrane 
bound IgM, and remain in a resting state until antigen activation.
2. B Cell Activation- Plasmablasts, Plasma Cells, and Memory Cells
Upon antigen activation, B cells will terminally differentiate into one of three 
fates: short-lived plasma cell, long-lived plasma cell, or memory B cell. Similar to early 
B cell development, this process follows a regulated sequence of events, beginning with 
plasmablast proliferation. During terminal differentiation, B cells will either remain in 
their final secondary immune tissue location or return to the primary immune tissue 
where they can survive within supportive niches as long-lived plasma cells. As observed 
in earlier stages of B cell development, the process o f terminal differentiation and plasma 
cell survival is highly dependent on both transcription factor expression and the 
microenvironment.
In the secondary immune tissues, mature resting B cells encounter antigen, 
activate, and then begin proliferating as antibody secreting plasmablasts. Plasmablasts are 
primarily found in the spleen or in the blood stream migrating to other tissues. In both
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mammals and teleosts, proliferating plasmablasts are also present in bone marrow 
(anterior kidney for teleosts), spleen, and blood [16]. The peripheral blood of teleosts 
contains plasmablasts but lacks plasma cells, as exemplified by the lack o f cell antibody 
secretion in the presence of the cell cycle inhibitor, hydroxyurea (reviewed in [45]) [3]. 
However, plasmablasts isolated from peripheral blood are incapable o f differentiating to 
mature plasma cells in vitro [16], emphasizing the importance of microenvironmental 
factors such as the presence o f cytokines, on B cell terminal differentiation [3]. It is not 
known whether peripheral blood B cell terminal differentiation occurs in vivo.
One key developmental marker o f proliferating and differentiating B cells is the 
X-box binding protein, Xbpl. Xbpl is a key regulator of the unfolded protein response 
and its expression allows antibody-secreting cells to accumulate proteins in the 
endoplasmic reticulum without triggering the unfolded protein response [46-48]. During 
mammalian and teleost plasmablast proliferation, Pax5 is downregulated, thus reversing 
the Pax-5 mediated inhibition of Xbpl [49]. Xbpl upregulation facilitates the production 
of IgM [48], the isotype of naive B cells. Flow cytometric analyses have utilized 
combinations of antigenic markers of Xbpl-S (the stable form of protein induced by 
antigenic stimulation), HCmu (the heavy chain o f IgM), and Pax5 to distinguish 
subpopulations of differentiating plasma cells in both trout and mouse by their distinct 
expression patterns [16]. When compared to mouse cells, trout cells do not produce as 
high a frequency of activated B cells when cultured in LPS (see [50] for use), however 
both trout and mouse plasmablasts exhibit intermediate levels of Xbp and HCmu as Pax5 
levels decrease. As plasmablasts differentiate to plasma cells, they express very high
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levels of Xbpl and HCmu and no longer express Pax5. Thus, the patterns of Xbpl 
expression and other conserved molecular markers provide conclusive evidence that 
plasmablasts are a conserved population distinct from plasma cells.
A plasmablast’s differentiation into a short-lived plasma cell is accompanied by 
important changes in IgM expression. Plasma cells are antibody-secreting cells that 
downregulate membrane IgM and they therefore no longer bind antigen. Instead, 
mammalian plasma cells upregulate and secrete Ig of various isotypes including IgM 
(reviewed in [51]). These short-lived plasma cells can be identified by their lack of 
somatic hypermutations; B cells with less specific binding to the antigen will undergo Ig 
somatic hypermutations to increase specificity. Teleosts also upregulate secreted forms 
of Ig, but with less isotype switching. Initially, IgM was proposed to be the only secreted 
teleost Ig, but recent studies indicate the additional presence o f secreted IgD and IgT [52- 
54]. The lack of mutational variability within the secreted Ig population is important as it 
suggests primary antigen exposure and can be used to distinguish short-lived plasma cells 
from long-lived plasma cells and memory cells.
Long-lived plasma cells (LLPCs) are plasma cells that have been previously 
exposed to antigen and thus secrete high affinity antibody [51]. The term “humoral 
memory” is applied to LLPCs as they can maintain active antibody secretion for months 
to years without re-exposure to antigen. In mice, LLPCs arise from a distinct plasma cell 
precursor population in the bone marrow [55]. These precursors differentiate to LLPCs 
and are maintained in a bone marrow niche of specialized stromal cells [51, 55]. Just as 
the mouse bone marrow harbors LLPCs, evidence suggests a similar role for the trout AK
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[reviewed in[56], [3, 57]. Upon antigen stimulation, these cells within the anterior kidney 
will continue to secrete antibodies weeks beyond those in the blood and spleen [3]. 
Furthermore, they do not require further antigen stimulation to remain active, Ig- 
secretors. Although not yet reported, it is likely these cells are supported within anterior 
kidney niches similar to those within mouse bone marrow [56].
In addition to differentiating into short-lived and long-lived plasma cells, 
activated B cells may also acquire a memory cell phenotype. Mammalian memory cells 
are distinct from plasma cells in that they continue to express membrane Igs. However, 
these memory cells have often undergone both isotype switching and somatic 
hypermutation o f their variable gene segments (reviewed in [23]). Mammalian memory 
cells are further defined as cells that rapidly increase antibody production upon antigen 
re-exposure and produce higher affinity antibodies than those generated during the 
primary immune response. The teleost immune system also exemplifies memory 
responses as production of a secondary immune response in trout immune cells increases 
antibody secreting cells without altering the number of antigen-sensitive clones.
However, unlike mammalian memory cells, teleost memory cells do not appear to exhibit 
affinity maturation (the production of antibodies with higher antigen affinity) [23, 58].
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Primary im m une tissue Secondary im m une tissue
Early dev. B Late dev. B IgM-secreting B 
< > < > < >
CLP pro-B
early
pre-B
late pre-B/ 
(im)mat.B act. B PB PC
Ikaros + + + +/- + /- + / - —
E2A + + + /- — — + —
EBF1 + + + /- + /- — — —
Pax5 — + + + + + —
Blimpl - - - - - + ++
Xbpl ++ ++ + +/- ++ ++ ++
RAG1 + + + /- — — — -
cHCmu — — — + + ++ ++
BrdU +/- + /- + - - + -
FSC high high high low low high high
Figure 1.1. Stages of B cell development characterized by molecular patterns 
(adapted from [3]). +/- delineates positive/negative expression of antibody in cell. 
CLP: common lymphocyte progenitor; B: mature B cell; PB: plasmablast; PC: 
plasma cell; FSC: forward angle light scatter. High FSC is characteristic of large 
cells.
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3. The Role of Pax5 in B Cell Commitment
The transcription factor Pax5 is considered to be a key regulator of B cell lineage 
commitment and is additionally expressed in both the developing central nervous system 
(CNS) and the adult testis [59]. As a member of the paired box (Pax) family of 
transcription factors, Pax5 shares a conserved DNA-binding domain of 128 amino acids 
known as the paired domain. Pax5 is necessary in developing B cell populations as it 
activates genes involved in B cell receptor formation and represses genes directing 
alternative lineage fates [60-63]. Its subsequent downregulation is critical for plasma cell 
proliferation and terminal differentiation. Given its crucial role in the early proliferative 
stages o f B cell development, it is not surprising that misexpression of Pax5 leads to 
oncogenesis. Additionally, Pax5 is one of the many genes processed via alternative 
splicing, although the role of multiple Pax5 isoforms in B cell development, activation, 
and cancer formation remains poorly understood.
3.1 Pax5 and Pax Family
The Pax family consists of nine transcription factors which express a conserved, 
bipartite paired domain and some or all o f two additional motifs (see Figure 1.2 for Pax5) 
[64]. X-ray crystallography demonstrates that the two sub-regions o f the paired domain 
include an N-terminal PAI domain encoded by exon 2 and a C-terminal RED domain 
encoded by exon 3 [65]. These domains bind two half-sites on adjacent DNA major 
grooves [66]. The Pax family is further divided into four classes by the presence of a 
conserved homology region called the homeodomain and an octapeptide repeat region
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(reviewed in [67]). Class one, consisting of Pax 1 and 9, contains the octapeptide region, 
but no homeodomain. Class two, consisting of Pax2, 5, and 8, has the octapeptide region 
and a partial homeodomain which lacks the ability to bind DNA. Class three, consisting 
of Pax3 and 7, has both the octapeptide region and a full homeodomain. Finally, class 
four contains Pax 4 and 6, displaying the full homeodomain and no octapeptide repeat.
Pax5 falls into a transcription factor family with unique homology region 
properties and transactivating potential. The partial homeodomain homology region 
allows for interaction with the TATA-binding protein at the gene promoter, enabling 
Pax5 to directly manipulate gene transcription [68]. This region also contains a binding 
m otif for the retinoblastoma gene product which is important in tumor suppression [68, 
69]. The Pax5 octapeptide motif interacts with the Groucho family of corepressors to 
repress gene transcription [70]. The C-terminal domain o f Pax5 contains a 55 amino acid 
transactivating domain which is serine/threonine/proline-rich. The transactivating domain 
is negatively regulated by inhibitory sequences in the extreme C-terminus [71].
In addition to their homology regions, Pax family members share commonalities 
in their conservation across species, alternative splicing patterns [9, 72-74] and oncogenic 
properties [67]. Pax genes are shared amongst mammals and lower vertebrates such as 
zebrafish, Xenopus, trout, and amphioxus [71, 72, 75-77]. Alternative splicing (reviewed 
later in this chapter) has been identified for each of the classes with the majority of 
isoforms containing an exon 2 deletion (for review, see [72]), resulting in a non­
functional paired domain.
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3.2 Pax5 in B Cell Development and Activation
Functional studies o f Pax5 using knockout and targeted mutation approaches 
demonstrate its role in B cell development and activation. Immune cells of mutant mice 
homozygous for Pax5 deletions are unable to proceed past the pro-B developmental stage 
[7]. These cells are capable of undergoing D-J rearrangements at the HC locus, but 
express significantly reduced V-D-J rearrangements (reviewed in [78]) [5]. Arrested pro- 
B cells are not restricted to the B cell lineage: culturing these cells in the presence of 
lineage-specific cytokines allows redirection of cell fate. Furthermore, Pax5 re­
expression via viral induction is sufficient to reverse the pro-B arrest and completion of B 
cell differentiation [6].
Pax5 alters B cell development through a mechanism of gene activation and 
repression [63]. Delogu et al. [61] identified 110 genes repressed by Pax5, and 
demonstrated that continuous Pax5 mediated repression of alternative lymphoid and 
myeloid genes was required to maintain the B cell lineage. It is therefore unsurprising 
that release of Pax5 repression is necessary for terminal plasma cell differentiation. In 
addition to genes related to cell adhesion and cellular migration, Pax5 also represses 
genes involved in isotype expression. Specifically, murine Pax5 binds and represses the 
enhancer of HC 3 a, as demonstrated via transient transfection studies of pro-B, pre-B and 
mature B cell lines [79, 80]. Pax5 also suppresses transcription of the Ig J chain gene, a 
process which must be reversed before cytokines such as interleukin-2 [81 ] and the 
transcriptional repressor Blimp-1 [82] can induce terminal plasma cell differentiation.
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More recently, Schebesta et al. [60] used microarray technology to identify 170 
Pax5-activated genes in murine pro-B cells, half of which are subsequently 
downregulated in plasma cells (reviewed in [83]). One of the potential mechanisms of 
Pax5 gene activation is histone modification, as evidenced by ChlP-on-chip studies [60]. 
These studies define active histones by the patterns of histone lysine methylation and 
acetylation (i.e. H3K4me2, H3K4me3, and H3K9ac). Microarray studies demonstrate the 
necessity of the Pax5 DNA binding domain for these active histone marks: upon Cre- 
mediated conditional knockout of the Pax5 DNA binding domain, pro-B cells exhibit 
fewer active histone marks than pro-B cells with intact versions of wildtype Pax5 [83]. 
Recent studies have further demonstrated that Pax5 induces changes in histone activation 
by recruiting chromatin remodeling and histone modifying complexes [62]. Pax5 is also 
necessary to activate genes involved in cell cycle regulation and metabolism [60], 
suggesting the expansive role of the transcription factor in developmental processes.
3.3 Pax5 Alternative Splicing
Alternative splicing is a mechanism by which the exons of an RNA transcript are 
differentially combined to produce different functional protein products. By recombining 
RNA exons in multiple ways, alternative splicing enables an economical means by which 
a single gene can encode multiple protein isoforms. The Pax family is one o f several 
transcription factors subjected to this process [9, 72-74]. The first Pax isoforms observed 
were those o f Pax8; four alternatively spliced Pax8 mRNA transcripts were identified in 
human kidney cells lines via PCR amplification and RNAse protection assays [73].
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Further analysis with transient transfection assays demonstrated that each isoform has 
distinct C-terminal transactivating properties. Unique patterns of Pax8 mRNA transcripts 
were also identified in mouse cell lines representing different stages of embryogenesis, 
suggesting the isoforms are carefully regulated during development.
Shortly after researchers identified Pax8 alternative splicing, similar observations 
were made for the additional Pax family members, including Pax5. The murine Pax5, 
identified in pro-B cell lines, mature B cell lines and spleen cells, has four distinct 
isoforms - Pax5a (full length: FL), b, d, and e (see Figure 1.2) [9]. Pax5b and e have 
deletions in exon 2, leading to a truncated, non-functional DNA-binding domain. Studies 
o f plasma cell lines suggest that low levels of Pax5b are present in the cell line SP20, one 
of three plasmacytoma lines tested [9]. In contrast, Pax5a is completely down-regulated 
in this same cell line. Subsequent functional studies demonstrated that although Pax5e 
alone is non-functional, in combination with Pax5a it may increase reporter gene activity 
[9, 84].
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Figure 1.2 [9]. Murine Pax5 isoforms shown as cDNA sequence. Numbers represent 
nucleotide number. Red box: paired domain (exons 2 and 3); purple: octamer region 
(exon 5); yellow: homeodomain homology region (exon 6); green: transactivation domain 
(exons 8 and 9); bright red: repressor domain (exons 9 and 10); blue: novel C-terminus.
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Similar to Pax8, murine Pax5 isoforms d and e have alternatively spliced C- 
termini, creating novel C-termini and deleted homeodomains. The novel C-terminal 
region contains significantly fewer Ser/Thr/Pro residues than Pax5a, altering its 
transactivating potential [9]. Functional studies o f Pax5d reveal that the isoform binds 
DNA with the same affinity as Pax5a and thus acts as an inhibitor of Pax5a in a dose- 
dependent manner [84]. The inhibitory role o f Pax5d is further emphasized by its 
decreased presence in LPS activated cells [84]. As Pax5a is needed for cell proliferation, 
it is logical that the inhibitor of Pax5a would be downregulated during B cell activation. 
Interestingly, while the Pax5a DNA-binding affinity is decreased in B lymphocytes of 
aged mice, the Pax5d DNA-binding affinity remains constant, further suggesting a unique 
role for Pax5d in B cell processes [85].
Remarkably, similar Pax5 isoforms are observed across species, including but not 
limited to humans, mice, fish (see Figure 1.3; Zwollo, unpublished data), and amphioxus 
[9, 12, 72]. Flumans [12], trout (Zwollo, unpublished data), and amphioxus [72] have 
isoforms that either include or exclude exons 7-9, drastically altering their transactivating 
potential. Likewise, conserved deletions o f exon 2 (the DNA-binding domain) in 
amphioxus, trout (Zwollo, unpublished data), mouse, and human isoforms [9, 10, 72] are 
particularly noteworthy. However, beyond a few functional studies o f isoforms lacking 
exon 2, a definitive role for expression of this isoform has yet to be identified.
Numerous studies have examined the role of aberrant Pax5 isoform expression in 
cancer development. Pax5 is considered a proto-oncogene since its misregulation often 
correlates with lymphomas and leukemias [86]. Haploinsufficiencies of full length Pax5
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correlate with acute lymphoblastic leukemia (ALL; [87]) whereas alternatively spliced 
Pax5 variants correlate with cancer formation. Robichaud et al. [12] found that human 
lymphoma samples express a reduced number of Pax5 isoforms, specifically the full 
length Pax5 and the Pax558 (lacking exon 8), in comparison to healthy samples which 
express multiple isoforms. Additionally, the expression of a novel Pax5 exon discovered 
by Borson et al. [11] is downregulated in patients with multiple myeloma. Despite the 
promise in these results, other studies have been unable to identify a single pattern of 
isoform expression that could be used to distinguish normal from malignant B cells [10]. 
Similarly, researchers have cautioned the testing of alternative splicing in cancer cells as 
unrelated stress factors such as overnight sample shipping may induce increased Pax5 
isoform expression [88]. Thus, although multiple splicing patterns have been reported in 
malignant cells, further analysis is required to establish any conclusive or diagnostic 
correlations.
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Figure 1.3. Trout Pax5 isoforms shown as cDNA sequence (adapted from Zwollo, 
unpublished data). Red box: paired domain; purple; octamer region; yellow: 
homeodomain homology region; green: transactivating domain; bright red: repressor 
domain; T : additional C-terminal amino acids.
20
4. Rationale for the Current Study
Although the role of Pax5 in B cell development and activation has been well 
described, the temporal-spatial expression patterns, functions, and consequences of 
multiple Pax5 isoforms in these processes remain unknown. Numerous studies emphasize 
the importance of Pax5-regulated gene activation and repression in B-cell development 
[60, 61]. Through conditional knockouts targeting Pax5 exon 2, repressor studies reveal 
the necessity of the DNA-binding domain in the activation o f B cell commitment genes 
[60]. Additionally, full length Pax5 (Pax5 FL) knockouts reveal the importance of Pax5 
inhibition. Without the transcription factor, cells re-express previously Pax5-inhibited 
genes. However, what these studies fail to address is the function of specific Pax5 
isoforms, including Pax562, in gene targeting. Functional studies exploring Pax5 
isoforms with paired domain deletions and novel C-termini have indicated a role for these 
isoforms in increasing Pax5a gene activation [84]. Therefore, it is likely these isoforms 
contribute to B cell developmental processes and mechanisms of regulation.
Additionally, identifying the function of these isoforms across species will help 
elucidate the evolutionary forces driving immune system development. A cross-species 
analysis may also enable researchers to identify the most relevant isoforms in B cell 
development and disease. As previously stated, the rainbow trout is an excellent model 
organism for cross-species comparisons. Despite lacking bone marrow and lymph nodes, 
its immune system functions similarly to that in humans. Furthermore, almost no 
published studies have compared B cell development in teleosts versus mammals, 
including studies o f Pax5 isoform expression and function.
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The first step in evaluating the functional potential of Pax5 isoforms is to identify 
their existence in individual B cell populations. Previous studies have primarily utilized a 
traditional or nested PCR approach requiring RNA from pooled cell samples to identify 
novel Pax5 isoforms [9, 72, 89]. While this approach is sufficient to identify the existence 
of Pax5 isoforms, it does little to assess their expression within individual developing, 
proliferating, and differentiating B cell populations. The frequency of cells representing 
specific B cell sub-populations is potentially quite small [2, 16, 76]. If individual 
isoforms function in these small, transient populations, a PCR approach will be unable to 
demonstrate the relative abundance (and potential importance) of these isoforms 
compared to isoforms found in larger B cell populations. Thus, a novel approach utilizing 
flow cytometry is necessary to elucidate the expression and potential role of Pax5 
isoforms in B cell development.
Studies have previously employed flow cytometry to establish “B cell signatures” 
or cytometric patterns representing the frequency and intensity of conserved molecular 
markers that demarcate B cell populations in different immune tissues [16]. As a 
fingerprint identifies an individual, flow cytometric analysis has successfully 
distinguished between trout and mouse immune tissues by demonstrating each immune 
tissue’s distinct frequency of developing B cell populations, including CLPs, pro-B, pre- 
B, mature B, proliferating, and plasma cells [2, 32, 76]. Furthermore, lymphocyte cells 
stained with antibodies against the Pax5 paired domain and analyzed by flow cytometry 
demonstrate the patterns of paired domain expression in B cell populations previously 
delineated in the literature. Therefore, flow cytometry provides a reliable and
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reproducible means of characterizing both B cell populations and whole immune tissues. 
Therefore, the aim of the current study was to use flow cytometry to evaluate patterns of 
Pax5 isoform expression in developing mouse and trout B cell populations and to 
characterize the “Pax5 signatures” of mouse and trout immune tissues.
5. Flow Cytometric Analysis
Flow cytometry is a technique used to identify cells by the key molecular markers 
o f individual cells comprising a larger population. Cells from tissues are stained with 
fluorescent-tagged antibodies and are then run single file through a laser beam, collecting 
information on the cell’s fluorescence, its forward light scattering, and its side light 
scattering. Each cell passing through the laser is considered an “event” and the 
fluorescence and light scattering information for each event is captured in a computer 
graphic that can be easily read by the researcher.
5.1 Flow Cytometer Fluids
The simple set up for flow cytometry is diagrammed in Figure 1.4. Cells are 
drawn up from a 96-well plate, mixed with sheath fluid (a proprietary buffer saline 
solution with detergent), and pushed through a flow chamber via laminar flow. In the 
flow chamber, cells are aligned single file by hydrodynamic focusing [90]. After passing 
through a laser beam, the cells are discarded into a waste container.
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5.2 Forward Angle Light Scatter (FSC) and Side Angle Light Scatter (SSC)
As cells are excited by a laser, light is scattered based on the size and complexity 
(indication of shape due internal cellular components) of the cell. FSC is light diffracted 
from the cell in the direction of the laser beam. Larger cells will have greater FSC than 
smaller cells. The FSC light is detected by a lens and translated into electronic pulses by 
a photodiode [90]. SSC is light reflected and refracted at 90° and is based on the cell’s 
topography (membrane roughness), cytoplasmic granularity, and shape of organelles.
SSC is only 10% of total light scattering and therefore must be detected by a more 
sensitive device such as a photomultiplier tube (PMT), which will amplify the weak 
signal.
5.3 Fluorescence
The BD FACS Array Bioanalyzer can detect fluorescence from four regions o f the 
light spectrum: infrared (IR), yellow, red, and far red. The emitted sample fluorescence 
is directed towards the optical filters using a series of mirrors and beam splitters. The 
filtered light is then amplified with a PMT and converted into electrical signals which can 
be read by the computer. If fluorochromes overlap in their emission spectra, BD 
FACSArray provides a compensation tool to collect data from fluorochromes only within 
a specific wavelength range.
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Figure 1.4. Flow cytometer process. Light blue arrows delineate cell pathway; bright blue 
arrows represent laser pathway. Single cell suspensions are mixed with sheath fluid and 
cells are passed individually through a laser beam. As cells pass through the beam, light 
is scattered and the direction of the scattering is detected by an optic lens. Additionally, 
the laser excites antibody fluorochromes. The light emitted from individual 
fluorochromes is passed through optic filters to detectors. The information is then passed 
to a computer which presents the intensity o f light scattering and fluorochrome 
fluorescence in a graphic image.
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5.4 Data Interpretation
Information from each cell is presented graphically on the computer as it is passed 
through the laser. A typical experiment will collect around 30,000 events, a high number 
designed to detect even small cell populations, such as plasma cells. During a typical 
experiment, multiple graphs will be used at once to examine the size o f the cells versus 
the complexity, the size of the cells versus their fluorescence, expression of one 
fluorochrome-labeled antibody versus a second fluorochome-labeled antibody, and a 
histogram for the number of cells expressing a fluorochrome at any given intensity of 
fluorescence.
When studying lymphocytes, the lymphocyte population is first gated based on a 
graph o f FSC versus SSC. Previous experiments have already identified how lymphocyte 
populations should appear on the FSC v. SSC graphs [2]. Figure 1.5 provides an example. 
This graph can be examined both in dot plot form (Figure 1.5a), where each cell is 
represented as one dot on the graph, or in contour form (figure 1.5b), where populations 
o f cells are represented by varying degree of intensity. Once the lymphocyte cells are 
gated, the population of cells may be examined for their fluorescence intensity of a 
particular antibody (see Figure 1.5c). In the example provided, the cells have been stained 
for two antibodies: one in the yellow emission wavelength and one in the red wavelength. 
The frequency of cells in a given population can be identified based on the four criteria 
listed above. Thus, flow cytometry provides a valuable means to characterize tissues 
composed of diverse cell populations.
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Figure 1.5. Flow data graphs. Ab = antibody. A) Cells individually recorded as “events” 
and separated according to size (FSC) and complexity (SSC). The region of lymphocytes 
is gated as population R l. B) The same population of lymphocytes is represented in 
contour form. C) Four populations o f cells stained for two antibodies are presented. Ab 1 
emits light in the yellow wavelength and Ab 2 emits light in the red wavelength. The 
populations of interest are boxed. Population R2 has high Ab 1 staining and medium Ab2 
staining. R4 has low or no Ab 1 staining and medium Ab 2 staining. R3 is high in Ab 1 
staining and high in Ab2 staining. The unboxed region represents a double negative for 
Ab 1 and Ab 2 staining.
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6. Hypothesis and Research Aims
Pax5 regulates B cell development through a process of coordinated gene 
activation and repression. Pax5 isoforms are able to enhance and inhibit full length 
Pax5’s ability to activate gene expression, thus potentially altering the course of B cell 
development. Therefore, this study predicted that Pax5 isoform patterns are differentially 
expressed in developing and activated B cell populations, forming unique Pax5 
signatures. This study hypothesized that specific Pax5 isoforms modulate Pax5 activity, 
thus altering B cell development and activation (see model in Figure 1.6). For example, 
Pax5 FL is able to activate genes necessary for B cell development; other isoforms such 
as the Pax552 (lacking exon 2) may inhibit the activation of these genes. Similarly, Pax5 
FL is downregulated to allow for plasma cell terminal differentiation. Isoforms lacking 
exon 2 may induce plasma cell differentiation.
To address this hypothesis, this study presented four research aims:
1) Identify trout Pax5 isoforms in developing B cells using two-color and tri-color 
flow cytometry.
We stained single cell suspensions with combinations of antibodies against 
specific Pax5 domains in addition to markers o f B cell development. We 
distinguished populations o f developing B cells across the anterior kidney, blood, 
and spleen using established B cell flow cytometric patterns. We analyzed the 
frequency of B cell populations expressing specific Pax5 domains and the 
intensity o f Pax5 domain staining within a given B cell population.
28
2) Examine trout Pax5 isoform expression after LPS activation using two-color flow 
cytometry.
We cultured trout blood and spleen cells in the presence o f B cell mitogen E. coli 
lipopolysaccharide. We analyzed Pax5 domain expression and cell proliferation 
exemplified by EdU incorporation across tissues.
3) Compare and contrast murine and trout Pax5 isoform expression during 
development and activation.
We analyzed mouse bone marrow and spleen cells using two-color and tri-color 
flow cytometry. We obtained the frequencies o f developing B cell populations 
expressing specific Pax5 domains and compared these to trout B cell populations.
4) Identify the preliminary differences in Pax5 isoform expression in trout resistant 
and susceptible to flavobacterium.
We identified B cell populations using the above listed methods. We compared 
the frequencies of B cell populations across immune tissues and the frequencies of 
populations expressing specific Pax5 domains between fish. Additionally, we
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identified changes in B cell populations after LPS activation and we analyzed 
differences in proliferating populations based on EdU incorporation.
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Effect o f Pax5 isoforms on activator target genes:
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Effect o f Pax5 isoforms on repressor target genes:
PCM a tu re  B
Figure 1.6. Model of Pax5 isoform modulations of B cell development. Top: During 
development, full length (FL) Pax5 is necessary to activate genes promoting B cell 
development. Isoforms that inhibit Pax5.FL may inhibit pre-B stages of development. 
Bottom: B cells must downregulate Pax5 repression of genes necessary for terminal 
plasma cell differentiation. Isoforms lacking exon 2 are unable to bind DNA and 
therefore cannot inhibit plasma cell differentiation. Isoforms lacking the repressor 
domain will permit Pax5 transcription, inhibiting plasma cell differentiation.
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Chapter 2. Manuscript
2.1 Introduction.
The mechanisms of B cell development and activation are highly complex and the 
tissues supporting B cell development are uniquely diverse across species. Even with 
such species diversity, the stages o f B cell development and molecular players are fairly 
conserved. In adult mammals, the bone marrow functions as the primary immune organ 
and site of hematopoiesis. In this tissue, hematopoietic stem cells produce common 
lymphocyte progenitors (CLPs) with the competency to form B cells. B cells progress 
through stages of immunoglobulin chain rearrangements, delineated as progenitor-B (pro- 
B), pre-Bl, large-pre-BII, small pre-BII, and immature B cell stages [13, 15]. Once B 
cells acquire functional B cell receptors, they migrate to the spleen (SPL) or other 
secondary immune organs where they function as mature B cells, and may encounter 
antigen, proliferate and differentiate into antibody-secreting plasma cells.
While previous research has extensively examined mammalian B cell 
development, only recently have researchers made significant insights into the teleost B 
cell system [2-4, 16, 32, 50, 76]. In contrast to mammals, teleosts lack bone marrow and 
alternatively utilize the anterior kidney (AK) as their primary immune organ [2, 3]. 
Similar to mammals, mature teleost B cells reside in the spleen, encounter antigen, and 
differentiate into plasma cells [3]. Additionally, some plasma cells will migrate back to 
the primary organ where they will reside as long-lived plasma cells [3].
Although the surfeit o f mammalian serological reagents is unavailable for 
deciphering teleost stages of B cell development, recent research has employed suitable
32
alternatives [2, 16, 32, 76]. Conserved transcription factor expression demarcates stages 
of B cell development in both mammals and teleosts [13]. Early developing B cells are 
characterized by high expression of Ikaros, EBF, Xbpl, and RAG 1/2 (see Table 1). 
Mature B cells express Pax5 combined with low levels of IgM, while antibody-secreting 
cells express high levels of IgM but no Pax5 [32].
Pax5 is a particularly intriguing transcription factor because of its conserved role 
in regulating B cell commitment in vertebrate species [7, 63]. It is transcribed from an 
alternatively-spliced RNA transcript and similar Pax5 isoforms are observed in humans, 
mice, trout and amphioxus [2, 71, 72, 77]. Pax5 expression is first observed at the pro-B 
stage and Pax5 homozygous deficient B cells will arrest at this stage [5,7]. During B cell 
development and activation, Pax5 targets genes necessary for B cell commitment while 
downregulating genes necessary for alternative lineages [60-63]. Expression o f Pax5 
continues until terminal B cell differentiation. During B cell differentiation, the 
transcription factor Blimp 1 represses Pax5, allowing expression of the B cell activation 
marker Xbpl [49].
The developmental role of the full length Pax5 isoform has been described by 
many groups, but little is known about the potential function of alternatively spliced Pax5 
isoforms. Using RT-PCR approaches, such isoforms have been observed and examined 
in primary cells and malignant cell lines [10-12, 86, 87]. Thus far, no strong correlations 
have been observed between isoform type and cell strain or malignancy, although 
researchers have demonstrated the differences in transactivating potential o f multiple 
isoforms in addition to their modulating effects on full length Pax5 [12, 84],
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Current studies are limited in their ability to correlate Pax5 isoforms with distinct 
developing B cell populations due to the use of pooled cells, either at the RNA level (RT- 
PCR) or protein level (western blot analysis). However, recent research in our lab has 
made use of flow cytometric analyses and antibodies against conserved, B cell specific 
transcription factors to begin identifying individual rainbow trout B cell populations at 
the various developmental and activated stages [2, 16, 32, 76]. Our research has 
demonstrated that early developing B, late developing B, and antibody-secreting B 
lymphocyte populations can be characterized through the combinatorial expression of 
specific developmental markers. These expression patterns form “B-cell signatures”, or 
flow cytometric patterns that characterize a particular immune tissue.
On the basis o f our prior studies, we hypothesize that certain Pax5 isoforms are 
present during limited, specific stages of B cell development as a means of modulating 
Pax5 activity. We predicted that we could further classify rainbow trout B cell 
populations by their patterns of Pax5 domain expression. Here, we report on the flow 
cytometric analysis of both resting and activated trout immune cells using Pax5 domain- 
specific antibodies. Our results reveal several unique B lymphocyte populations based on 
expression of different Pax5 proteins. We demonstrate that early developing, late 
developing, and activated B cells differentially express three Pax5 domains, encoded by 
exon 6 (Pax5.E6), exon 10 (Pax5.E10), and the paired domain (Pax5.PD). Examining the 
combinatorial expression o f Pax5 proteins with EBF, Xbpl-S, and HCmu, we provide 
evidence for the first time that early developing populations are present in the blood and 
spleen of rainbow trout.
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2.2 Methods.
Animals and facilities.
Rainbow trout (Onchorhynchus mykiss) were generous gifts from Dr. Steve Kaattari 
(Virginia Institute o f Marine Science). Fish were maintained in 100 gallon tanks with a 
recirculating system employing biologically-filtered well water. Water was maintained at 
12° C. C57BL/6J mice between 3-5 months of age were obtained from Jackson 
Laboratories.
Isolation o f  immune cells.
Fresh trout anterior kidney cells were obtained using methods previously described [2]. 
Briefly, the trout kidney was divided into subsections of seven vertebrae beginning at the 
posterior end (K5). The K1 region was collected in 5 mL sterile HBSS (137 mM NaCl,
5.6 mM D-glucose, 5 mM KC1, 8.1 mM Na2HP04-2H20, and 20 mM Hepes at pH 7.05). 
Similarly, mouse bone marrow and mouse and trout spleen were collected in HBSS as 
described previously [84]. Single cell suspensions were created by passing cells through a 
10 mL syringe followed by filtration through a 40 nm nylon filter (Falcon; BD 
Biosciences). Cells were then pelleted at 250 g  for 10 minutes and resuspended in cold 
HBSS. Cells were then either prepared for culturing (see cell culture and mitogens) or 
washed in IX PBS (1.9 mM NaH2P04 H20, 8.1 mM Na2HP04-7H20, 137 mM NaCl, and
2.6 mM KC1, pH 7.4) containing 0.02% sodium azide in preparation for fixation (see 
Fixation). Blood cells were washed in cold HBSS and layered onto Histopaque 1077
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cushions (Sigma Aldrich) and spun at 500 g  at 4 °C for 45 minutes. The peripheral blood 
(PBL) cell layer was removed and cells were either washed in cold HBSS for culturing or 
in PBS containing 0.02% azide for fixation.
Cell culture and mitogens.
Freshly isolated trout PBL and spleen cells were cultured at l.OxlO7 cells/mL in trout 
culture medium (TCM) consisting of RPMI 1640 with 10 mM [ -glutamine, 10% FCS, 50 
pg/ml gentamicin, 50 pM 2-ME, and the nucleosides adenosine, uracil, cytosine, and 
guanosine (final concentration 10 pg/ml; Sigma-Aldrich). Cells were maintained at 18 °C 
in the presence of blood gas and fed every other day with one tenth of the culture volume 
of a 10X tissue culture cocktail containing 500 pg/ml gentamycin, 10X essential amino 
acids (aas), 10X non-essential aas, 70 mM L-glutamine, 70 mg/ml dextrose, 10x 
nucleosides, and 33% fetal bovine serum (FBS). B lymphocytes were activated using 
mitogen LPS (from Escherichia coli 055:B5, pasteurized for 30 min at 70 °C in distilled 
water) at 100 pg/ml. For cell proliferation analysis, cells were incubated in the presence 
of 3 pM 5-ethynyl-2’-deoxyuridine (EdU; Invitrogen) for 17 hours immediately before 
collection.
Antibodies.
The polyclonal anti-paired domain (Pax5.PD) antibody (previously called ED-1) 
recognizes trout and mouse Pax5 and has been described previously [91]. The rabbit anti­
trout Pax5.E6 polyclonal antibody was raised against the injected Pax5 peptide
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HGPGGRDFLRKQMRGDL. The rabbit anti-trout Pax5.E10 polyclonal antibody was 
raised against the peptide sequence AASRGAGPAATATASAYDRH. Both antibodies 
were generated with GenScript. The monoclonal mouse anti-trout immunoglobulin heavy 
chain mu (HCmu 1-14; [92]) was a generous gift from Greg Warr. The tX bpl-S  antibody 
(referred to here as anti-Xbp 1) binds the stable form of Xbp 1 protein resulting from 
antigenic stimulation and has been described previously [16]. The polyclonal goat-anti- 
human Pax5.E10 IgG (Pax5-C20) detects the 20 C-terminus amino acids of human Pax5. 
The mouse Pax5.E10 and the rabbit-anti-human EBF IgG (H300; detecting amino acid 
residues 1-300 of EBF1, and reactive with mouse/human EBF2, 3, and 4) were 
purchased from Santa Cruz Biotech. The rat-anti-mouse IgM-PE was purchased from BD 
Biosciences. Isotype control antibodies included rabbit IgG, goat IgG (Molecular 
probes), or mouse IgG (eBiosciences) conjugated to Alexa Fluor 555 or Alexa Fluor 647. 
For flow cytometric analyses, unlabeled antibodies were conjugated (Alexa Fluor 555 
and/or Alexa Fluor 647) using protein labeling kits according to manufacturer's 
instructions (Molecular Probes). Antibody aliquots were stored in 1% BSA at -2 0  °C
Fixation and permeabilization o f  cells fo r  flow  cytometry.
Cell pellets were resuspended in freshly prepared 1% ice-cold paraformaldehyde (10% 
stock, EM-grade; Electron Microscopy Sciences) in PBS and fixed on ice for 15 minutes. 
Cells were then washed in IX PBS and resuspended drop wise (while vortexing) in 1 mL 
ice-cold 80% methanol. Cells were incubated overnight at -20 °C and stored at -20 °C 
until use (up to 3 weeks).
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Flow cytometry.
Cells were removed from -20 °C and an equal volume PBS plus 0.02% azide was 
immediately added. Cells were then pelleted and resuspended in 1 mL PBS and 0.02% 
azide. Cells were then resuspended in 1 mL permeabilizing solution (BD perm wash in 
PBS, BD Biosciences) containing 2% FBS and then incubated in perm wash + 5% FBS at 
a concentration of lx l0 7 cells/mL at 4 °C with gentle shaking. 0.5 x 106 cells were then 
transferred to each well on a 96-well polystyrene round bottom plate (Fisher).
Fluorescent Abs were added to the cell suspensions to a final antibody concentration of 
0.5-2 pg/0.5 x 106 cells/50 pi final volume, and cells incubated at 4 °C for 90 min in the 
dark with gentle shaking. Cells were next washed in 260 pi o f perm wash + 2% FBS 
followed by a 10 min incubation in the dark, shaking, at room temperature. The wash and 
incubation was repeated once. For three-color flow cytometry, an indirect staining 
approach was used for the third antibody by staining cells with a biotinylated HCmu in 
conjunction with steptavidin APC-750 (Sigma). For cell proliferation analysis, the 
nucledoside analog EdU and a Click-It kit (Invitrogen) was used according to 
manufacturer’s instructions. Cells were pelleted and resuspended in 200 pi perm wash 
containing 2% FBS and immediate analyzed. Approximately 30,000 events were 
acquired per sample using a BD FACSArray (BD Biosciences). Duplicate samples were 
analyzed for each experiment. Experiments were repeated a minimum of three times.
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Western blot analysis.
Trout cell suspensions were centrifuged in aliquots of 0.6 x 105 cells or 1.7 x 105 and 
pellets were quick-frozen at -8 0  °C. Whole-cell protein lysates were prepared by 
resuspending cells in 40 pi o f a sample buffer containing 5% 2-ME and proteins 
separated by size using denaturing 12% SDS-PAGE gels. Proteins were transferred onto 
a polyvinylidene difluoride (PVDF) membrane (Immobilon-P; Millipore). Membranes 
were incubated in blocking solution o f 5% dry milk in PBS containing 0.5% Tween 
(PBST) for 1 h, followed by a 2 h incubation in blocking solution in the presence of 
primary antibody: ED-1 (Pax5.PD; lpg/mL final dilution), Pax5.E10 (2 pg/mL final 
dilution) or Pax5.E6 (2 pg/mL). Four 5 minute washes in PBST were then followed by a 
1 h incubation with the secondary antibody goat anti-rabbit IgG-HRP conjugate 
(0.1 pg/ml; Zymed Laboratories) in blocking solution, and membranes were washed four 
more times for 5 minutes each in PBST and filters developed using a chemiluminescence 
kit (ECL-Plus; GE Healthcare Life Sciences).
Flow cytometric data analysis.
Contour graphs were generated using WinMDI 2-8 (J. Trotter 1993-1998) software at a 
2/0.1 threshold/smooth setting. Contour graphs are shown as log algorithms with 
intervals of 50%. Quadrants for LPS-activated samples were established by placing Q3 
on the double negative population o f the DO sample. All other gates were created by 
following contour lines. Statistics were obtained from WinMDI 2-8 software. Arithmetic 
means of population frequencies and standard errors were calculated for each experiment
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using Excel software. The change in relative intensity o f antibody staining over days of 
LPS activation was calculated for each experiment as follows: the average fluorescence 
o f a given antibody within the population of interest was calculated using WinMDI 
software and the highest fluorescence of the antibody within the experiment was given a 
100% intensity value. All other average fluorescent values were calculated as a 
proportion of the highest fluorescent value. In this manner, we were able to examine the 
relative changes in average fluorescence across days of activation.
2.3 Results and Discussion.
Previous studies have extensively examined Pax5 alternative splicing in immune 
tissues across species. However, these studies fail to identify the expression of Pax5 
isoforms in individual developing and activated B cell populations due to the use of 
pooled cells for RT-PCR. Here, we describe an alternative approach using flow 
cytometry on freshly isolated rainbow trout tissues. Fixed anterior kidney (AK), 
peripheral blood (PBL) and spleen (SPL) cells were permeabilized and stained with 
fluorescent antibodies targeting specific B cell markers and transcription factors (Figure 
1). Initially, three distinct antibodies were used to explore the presence of Pax5 
subpopulations in trout immune tissues. The Pax5.PD antibody recognized the paired 
domain of Pax5 and has been used in previous studies [2, 16, 32, 76]. A second anti-Pax5 
antibody recognized the region encoded by exon 6 o f Pax5, named Pax.E6. A third 
antibody, Pax5.E10, is specific to the C-terminal region of Pax5, encoded by exon 10.
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Figure 1. Diagram o f  trout Pax5 antibody specificity. Pax5.PD antibody recognizes  th e  paired  
d om ain  o f  Pax5; Pax5.E6 recongizes  a region e n c o d e d  by exon  6; Pax5.E10 recognizes th e  C- 
term inus (repressor dom ain). Each n um ber represents  th e  exon  en cod in g  th e  respective  Pax5 
dom ain .
To demarcate the identified B cell subpopulations, these three Pax5 antibodies 
were then used in combination with antibodies for the transcription factors X-box binding 
protein 1 (the processed form of Xbpl; [16]), EBF [32], and the marker of 
immunoglobulin heavy chain mu (HC mu; see Table 1; [2, 76]). Each of these antibodies 
had been used successfully in previous studies to define trout B cell populations. Xbpl is 
expressed at high levels in very early B cell stages (CLP, pro-B), is down-regulated 
during B cell maturation, and is strongly induced again during terminal B cell 
differentiation (see Table 1). HCmu is first expressed in immature B cells and expression 
increases throughout terminal B cell differentiation. EBF is highly expressed in CLP and 
pro-B cells, followed by downregulation as the B cell matures [16].
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Table 1. Expression o f Pax5 isoform and development markers during B cell stages.
Xbpl-S Pax5.E10 Pax5.PD Pax5.E6 EBF RAG1 EdU HCmu FSC
CLP ++ - - ++ + + + /- - H
Pro-B + + + /- + + + + /- - M/H
Small pre-B + +/- + +/- - - - + /- L
Mature B + + + + - - - + o r - M
Early Act. B + ++ + + - - - + M
Act. B ++ ++ ++ ++ - - - ++ M
Plasmablast ++ + + + - - + ++ H
T-Plasma cell ++ + + /- + - - - +++ H
M-Plasma cell ++ ? — ? _ _ — +++ H
Note: H: high; M: medium; L: low. Act.: activated. Expression demarcated by (+) sign, increased 
expression by (++) and highest expression by (+++).
2.3.1. Western blot analysis.
To verify that the three Pax5 antibodies recognized Pax5 protein, western blots of 
freshly isolated rainbow trout spleen, peripheral blood, and anterior kidney were 
prepared (Figure 2). Figure 2A shows that the Pax5.PD antibody recognizes the full 
length Pax5 protein, a protein with an approximate molecular weight of 48 kD which 
must represent full length Pax5. Using the same antibody, the level of Pax5 protein is 
significantly lower in anterior kidney compared to spleen and blood. Conversely, both 
the Pax5.E10 antibody (Figure 2B) and the Pax5.E6 antibody (Figure 2C) stained the 48 
kD (full length Pax5) protein in all three tissues. Additionally, Pax5.E10 recognized a 
lower molecular weight isoform in all three tissues. These results demonstrate that the
42
three Pax5 antibodies recognize the target Pax5 protein and furthermore show that each 
antibody recognizes Pax5 in a unique manner across tissues.
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Figure 2. W estern  blot analysis o f  trout sp leen  (SPL), blood (PBL), and anterior kidney (AK) using  
th ree  Pax5-specific antibodies .  Closed Triangle: full length Pax5; o p en  triangle: Pax5 isoform o f  
low er m olecular w eight.  M olecular w eigh t  markers (MWM) sh o w n  in kDA on left. First three  
lanes contain  0 . 6 x l 0 5 cells /lane; last th ree  lanes contain  1 . 7 x l 0 5 ce lls /lane.  A. Pax5.PD stain. B. 
Pax5.E10 stain. C. Pax5.E6 stain.
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2.3.2. Patterns of Pax5-expressing cells using three distinct trout Pax5 antibodies.
Multiple lymphocyte populations were identified in the anterior kidney, blood and 
spleen as shown in Figure 3A. In the anterior kidney, a low and high FSC population is 
present, as reported previously [32]. These populations are predicted to contain late and 
early developing B cells respectively. Blood was highly variable, consisting of two to 
three lymphocyte populations with unique low and high FSCs. Spleen contained one 
main population of lymphocytes and a smaller population of low FSC cells.
Permeabilized anterior kidney, peripheral blood, and spleen cells were first co­
stained with the anti-Pax5.E6 and anti-Pax5.E10 antibodies and analyzed by two-color 
flow cytometry (Figure 3B). For each tissue, three Pax5 subpopulations were identified: a 
Pax5.E6 high/Pax5.E10 low population (presumably all isoforms lacking the C-terminus 
of Pax5), a Pax5.E6 high/Pax5.E10 high population (cells expressing intermediate to high 
levels o f both E6 and E10 regions of Pax5), and a Pax5.E6 low/Pax5.E10 high population 
(cells lacking exon 6 staining). Table 2 lists a summary of each subpopulation’s mean 
frequencies and S.E.s.
When comparing the Pax5.E10 and E6 expression patterns between tissues, the 
most abundant population in all three immune tissues consisted of smaller lymphocytes 
that co-stained with both antibodies (the Pax5.E6 high/Pax5.E10 high population). For 
PBL and spleen, the frequencies of this co-staining population are consistent with 
previous findings [76], and likely represent resting mature B cells. For anterior kidney, 
the relatively high frequency of this population was unexpected.
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Figure 3. Two-color flow cytometry o f anterior kidney (AK), peripheral blood (PBL), 
and spleen (SPL). A) FSC and SSC of gated lymphocyte populations. B) Patterns for 
Pax5 using the Pax5.E6 and Pax5.E10 antibodies. Frequencies o f each population are 
given as mean % gated lymphocyte population. See Table 2 for all means and SEs.
Using the same two antibodies, a second population o f Pax5-expressing cells had 
high Pax5.E6 staining, but lacked a C-terminus (Pax5.E6 high/Pax5.E10 low). This 
population was most abundant in anterior kidney (25.0% ± 3.5) and least abundant in 
spleen (2.1% ± 0.7). This subpopulation consisted of large cells (high FSC), supportive 
o f their representing an early developing B cell population [32]. The possible presence of
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developing B cells expressing both exon 6 and exon 10 in secondary lymphoid tissues 
(PBL and spleen) was investigated and is discussed below.
Conversely, cells that expressed Pax5 proteins that lacked the region encoding 
exon 6 but which contained a C-terminus (Pax5.E6 low/Pax5.E10 high population) were 
present at low relative frequencies in anterior kidney (0.4%) and spleen (4.4%), and at 
high frequencies in the PBL (25%). These findings suggest that isoforms expressing the 
C-terminus may be more prominent in activated, terminally differentiating B cells. The 
high frequency of presumably activated/terminally differentiated (Pax5.E6 low/Pax5.E10 
high) cells in PBL was unexpected.
Next, trout tissues were stained with the same anti-Pax5.E10 antibody but now in 
combination with anti-Pax5.PD (the paired domain-specific antibody). Data are shown in 
Figure 4. In the spleen, the majority o f cells co-stained (43.9%) with the two antibodies, 
and similarly, PBL showed high (32.8 %) co-staining. Together with the Pax5.E6/E10 
data (Figure 3), this suggests that the main Pax5 isoform expressed in secondary immune 
tissues is the full-length form (PD+/E6+/E10+).
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Figure 4. Two-color flow cytometry using Pax5.PD and Pax5.E10 antibodies. Mean 
frequencies represent % gated lymphocytes. See Table 2 for all means and SEs.
Furthermore, using the same two antibodies, an anterior kidney-unique Pax5- 
positive population was detected which contained the paired domain, but not the C- 
terminus of Pax5 (Pax5.PD high/Pax5.E10 low; mean of 20.3%). While both spleen and 
PBL lack this population, both tissues have a population of Pax5-expressing cells that are 
somewhat the opposite: they lack the paired domain, but do contain the C-terminus (PD 
low/ El 0 high). In spleen an average of 16.4% of lymphocytes had this phenotype. 
Furthermore, these spleen cells exemplified a medium FSC, suggesting they are mature B 
cells high in C-terminal Pax5 expression and lower in paired domain Pax5 expression. 
Together with the data using Pax5.E6 and Pax5.E10 antibodies, this supports a role for 
the C-terminus of Pax5 in mature or activated B cells.
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Table 2. Average % frequency (S.E.) o f Pax5 subpopulations across im m une tissues.
Combination AK PBL SPL Figure*
Pax5.E6 high/Pax5.E10 low 25.0 (3.5) 14.0 (5.4) 2.1 (0.7) 3B
Pax5.E6 high/Pax5.E10 high 34.3 (3.8) 53.1(7.8) 56.4 (5.3) 3B
Pax5.E6 low/Pax5.E10 high 0.4 (0.2) 25.3 (4.3) 4.4 (1.4) 3B
Pax5.PD high/Pax5.E10 high 20.3 (1.7) 0.0 (0.0) 0.0 (0.0)** 4
Pax5.PD high/Pax5.E10 high 40.8 (6.8) 32.8 (13.1) 43.2 (3.8) 4
Pax5.PD low/Pax5.E10 high 0.0 (0.0)** 21.3 (9.9) 16.4(2.8) 4
Pax5.PD high/Pax5.E6 int. 30.3 (4.4) 31.3 (4.1) 44.7 (2.5) 5A
Pax5.PD high/Pax5.E6 high 0.5 (0.2) 6.1 (2.8) 2.4 (0.3) 5A
Pax5.PD low/Pax5.E6 high 27.8 (3.5) 10.7 (3.0) 1.3 (0.4) 5A
Next, two-color flow cytometry was performed using the remaining combination 
o f anti-Pax5 antibodies, namely anti-Pax5.PD and anti-Pax5.E6 (Figure 5). All three 
tissues show significant populations o f high paired domain, intermediate exon 6 
expressing (Pax5.PD high /Pax5.E6 int.) cells: spleen has 44.6%, blood 31.3%, and 
anterior kidney 30.3%. This suggests that these cells express full length Pax5 and 
represent mature B cells in spleen and blood, and either pre-B or immature B cells in the 
anterior kidney. It should be noted that upon tissue isolation, the anterior kidney tissue 
contains a fairly high amount of blood, which may affect the anterior kidney B cell 
frequencies and explain the relatively high percentage of paired-domain expressing 
(immature and mature B) cells in this tissue.
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Paired-domain-lacking populations were present in all three tissues: in anterior 
kidney, 27.8% of the lymphocytes stained strongly for Pax5.E6, but weakly for Pax5.PD 
(Pax5.PD low/Pax5.E6 high). Both PBL (10.7%) and spleen (1.3%) also contain a paired- 
domain-less Pax5 population (Figure 5). For this antibody combination, the expression 
pattern for Pax5.E6 expressing cells follows the patterns shown above (see Figure 3), 
with the highest frequency of Pax5.E6 expressing, but paired domain lacking and C- 
terminus lacking population (PD-/E6+/E10-) in the anterior kidney, and the lowest 
frequency in the spleen, suggesting that this population contains mostly early developing 
B cells. This is supported by FSC data; as shown in Figure 5B, the Pax5.PD low/Pax5.E6 
high population in anterior kidney primarily consists of large, high FSC cells, typically 
representing progenitor cells.
Lastly, using Pax5.PD and Pax5.E6 antibodies, a small population of high co- 
staining cells is present in all tissues, with the lowest frequency in anterior kidney (0.5%) 
and highest in the PBL (6.1%; Figure 5A). These cells likely contain full-length Pax5 
and have increased Pax5 expression; hence, they may represent activated or terminally 
differentiating B cells. This agrees with other reports that observe increased Pax5 
expression upon B cell activation [82], as well as with our own observations.
Furthermore, the cell size o f these high co-staining cells (Pax5.PD high/Pax5.E6 high) in 
spleen and PBL is considerably larger (medium to high FSC) than those o f the mature B 
cells (Pax5.PD high/Pax5.E6 int. cells), supportive of their being in a more activated 
state. The higher frequency o f this subpopulation in the PBL compared to spleen 
suggests that PBL contains more activated B cells than spleen.
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Figure 5. Two-color flow cytometry using the Pax5.PD and Pax5.E6 antibodies. A) Flow 
graphs depicting mean % frequency of each Pax5 subpopulation. See Table 2 for all 
means and SEs. B) FSC of each gated Pax5 population. Shaded line: all lymphocytes; red 
line: Pax5.PD high/Pax5.E6 int. population; green line: Pax5.PD low/Pax5.E6 high 
population; blue line: Pax5.PD high/Pax5.E6 high population. Each corresponding 
histograph is present below each flow graph.
50
In summary, using the three trout-Pax5 antibodies, we observed several patterns. We 
hypothesize that:
1. Some early developing B cells in the anterior kidney already express Pax5 isoforms
that lack the paired domain and the C-terminus. The Pax5 pattern for such cells is PD -
/E6+/E10- with a B cell signature of PD-/E6+/E10-/HCmu-/Xbpl+/EBF+.
2. The spleen and blood contain a minor population of early B cell progenitors with the 
Pax5 pattern PD-/E6+/E10+ with a B cell signature PD-/E6+/E10+ /HCmu- 
/Xbpl+/EBF+ . These cells are LPS sensitive and differentiate upon LPS activation.
3. The majority o f mature resting B cells express full-length Pax5 protein.
4. A subpopulation of mature B cells has higher Pax5 C-terminus expression and 
activated B cells upregulate full-length forms of Pax5.
5. Blood may contain more activated B cells than spleen.
2.3.3. Identification of early developing B cells with the Pax5 pattern PD-/E6+/E10- in 
the trout anterior kidney.
To test the prediction that some very early developing B cells in anterior kidney 
express Pax5 isoforms that lack both the paired domain and C-terminus, we stained cells 
with a combination of Pax5 antibodies and the tXbpl-S, HCmu, and EBF antibodies. 
First, to provide evidence that cells expressing high Pax5.E6 represent early lymphoid 
progenitors, we stained anterior kidney cells with both anti-Xbpl and anti-Pax5.E6 
antibodies. Results showed that Xbpl exhibited perfect co-staining with Pax5.E6 in all
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three tissues (Figure 6): cells that express high Xbpl also express high Pax5.E6, and cells 
that express low Xbpl also express low Pax.E6. Next, to distinguish between early 
developing B cells and IgM-secreting plasmablasts/pre-plasma cells (both of which co­
stain with Pax.E6 and which express high levels of Xbpl), we performed three-color flow 
cytometry with anti-Pax5.E6, anti-Xbpl, and anti-HCmu antibodies (Figure 6). Three 
Pax5.E6/Xbpl co-staining populations were gated: high, intermediate, and no-staining, 
named R2, R3, and R4 respectively (see Figure 6A). Histograms were then generated for 
HCmu intensity of each gated population (Figure 6B). Importantly, the results show that 
a subpopulation of cells with the highest co-staining for E6 and Xbpl (R2) lacked HCmu 
(Figure 6B, red line), in support of the prediction that most of these are early developing 
B cells. Cells from the intermediate population (R3) expressed intermediate to high 
levels of HCmu, suggesting these are the late developing B cells, while as expected, the 
R4 region also lacked HCmu expression. When the same experiment was repeated using 
anti-Pax5.PD instead of Pax5.E6, it was found that PD high cells do not express high 
levels o f Xbpl (data not shown). Together with the Pax5.PD data, this suggests that a 
subpopulation of anterior kidney cells express high levels of a Pax5 isoform that contains 
exon 6, but lacks a paired domain, while expressing high levels o f X bpl; such cells must 
represent early developing B cells, because they do not express immunoglobulin [16].
The FSC histogram supports this assumption, as the high co-staining subpopulation (R2) 
consists entirely of larger (high FSC) cells, a characteristic of early progenitors and 
transitional plasma cells. In contrast, the Pax5.PD cells are smaller, more mature cells 
(data not shown).
52
Formally, it is still possible that the PD-/E6+/Xbpl +/HCmu- cells are antibody- 
secreting cells that secrete an isotype different from IgM. To further establish early B cell 
identity, we used the anti-EBF antibody in combination with anti-Pax5.E6, anti-PD, or 
anti-Xbpl. A population of large cells (high FSC) that co-stained E6 and EBF, and Xbpl 
and EBF, was detected in anterior kidney, supporting that these are early developing B 
cells in the anterior kidney with the Pax5 pattern PD-/E6+/E10-.
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Figure 6. Three-color flow cytometry for Pax5.E6, HCmu, and Xbpl in AK, PBL, and SPL. A) 
Flow graphs depicting the coexpression of Pax5.E6 and tXbpl. Regions R2, R3, and R4 utilized 
for histogram analysis. B) Histogram of number o f cells within Pax5.E6/Xbpl regions expressing 
intensities of HCmu. C) Histogram o f FSC for cells within Pax5.E6/Xbpl regions. Grey shaded 
line: all gated lymphocytes; red line: R2; green line: R3; blue line: R4.
2.3.4. Identification of early developing B cells with the PD-/E6+/E10+ Pax5 pattern in 
the trout spleen.
Next, the presence of early developing B cells (Pax5.E6 high/Xbpl high) was 
tested in secondary immune sites. As expected, a population of mature B cells (high 
HCmu-expressing cells) was observed in the intermediate (R3) population in both spleen 
and PBL (Ligure 6B; green line). However, the highest co-staining population (R2, red 
line) contained both HCmu-staining and non-HCmu-staining populations. The HCmu- 
staining population likely includes IgM antibody-secreting cells, either transitional or 
mature plasma cells [32].
To address the possibility that some of the Pax5.E6 high/Xbpl high/ HCmu 
negative (R2) population in spleen contained early B cell progenitors, cells were stained 
with both Pax5.E6 and the early B cell marker EBL. Indeed, a small population of E6 
high/EBL high cells was detected (data not shown). This supports our hypothesis that 
trout spleen cells house a small population of early developing B cells.
We additionally tested if  cells high in Pax5.E10 expression also co-stained EBF.
In the anterior kidney, none of the EBF positive cells express HCmu [32]. In both the 
anterior kidney and spleen, EBF co-stained with cells expressing the Pax5-C terminus, 
suggesting that some early developing B cells have a Pax5 pattern PD-/E6+/E10+.
These cells likely represent a population of early progenitor B cells as they were larger in
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size, but did not costain with cells expressing the highest E6 and X bpl. In the spleen, this 
subpopulation had a frequency of 2-4%. Hence, our prediction that spleen contains a 
population of early developing B cells with the Pax5 pattern PD-/E6+/E10+ holds true. 
This population is different from the PD-/E6+/E10- population (Figures 3B and 5).
2.3.5. Differential expression of Pax5 isoforms during in vitro LPS-activation of trout 
spleen cells.
Three predictions needed to be tested in spleen cells: (1) that resting mature 
spleen cells express full length Pax5, (2) that spleen cells contain a small population of 
early developing B cells with the Pax5 pattern PD-/E6+/E10+ which differentiate upon 
activation, and (3) that activated B cells have increased expression levels of full-length 
Pax5. To test these predictions, we cultured spleen cells in the presence of mitogen LPS 
and analyzed cells on days 2, 4, and 7 after activation (see Figure 7).
Figure 7A displays the change in frequency of the major Pax5 lymphocyte 
population, the population that co-stained with Pax5 antibodies recognizing exons 6 and 
10 (Pax5.E6 and Pax5.E10), and which presumably express the full-length form of Pax5. 
The abundance of this co-staining subpopulation decreased significantly as cells became 
activated by LPS, with frequencies dropping from 52.7% on day 0 to 21.0% on day 7 (see 
Table 3 for mean frequencies and SEs). Conversely, a population of cells staining for 
exon 10 but not exon 6 (Pax5.E6 low/Pax5.E10 high), increased in frequency, from 8.4% 
on day 0 to 20% by day 7. A similar increase was observed when the Pax5.E10 antibody 
was used in combination with Pax5.PD: cells staining with exon 10 but not P P . This
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Pax5.PD low/Pax5.E10 high subpopulation increased from 14.6% on day 0 to 30.7% on 
day 7 (Figure 7B). In agreement with these patterns, the Pax5.PD/Pax5.E10 co-staining 
population (containing PD and exon 10) decreased in frequency during activation, 
demonstrating that cells stained with Pax5.PD decrease in frequency. Figure 7C 
represents the change in cell populations expressing paired domain and exon 6 across 
days o f activation. The frequency of the Pax5.PD high/Pax5.E6 low subpopulation also 
decreases during activation (consistent with the trends observed in Figure 7B) as does the 
Pax5.PD high/Pax5.E6 high subpopulation. The graphs also demonstrate a noteworthy 
decrease of the Pax5.PD low/Pax5.E6 high early developing population (Figure 7A and 
7C red circles) previously described in this study.
Together, these findings suggest that the frequency of cells expressing the paired 
domain decreases during activation. However, the frequency of cells expressing the Pax5 
C-terminus, but not the paired domain (Pax5.PD low/Pax5.E10 high), increases during 
activation. Lastly, the Pax5.E6 high early developing cells decrease during activation, 
suggesting they differentiate upon LPS activation, although cell death could also account 
for this decrease.
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Figure 7. Two-color flow cytometry for cells cultured in E. coli LPS. Days (D) represent 
day fixed after LPS exposure. Red circles indicate Pax5.E6 high early developing cells. 
Frequencies represent average frequency of cells in quadrant. A) Cells stained with anti- 
Pax5.E6 and anti-Pax5.E10 antibodies. B) Cells stained with anti-Pax5.PD and anti- 
Pax5.E10 antibodies. C) Cells stained with anti-Pax5.PD and anti-Pax5.E6 antibodies.
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To explore these patterns further, we measured if the changes in a population’s 
cell frequency during activation were accompanied by changes in the relative intensity of 
Pax5 exon 10 expression in individual cells. We focused on two small, but dynamic, 
populations. First, the predicted early developing Pax5.E6 high and Pax5.E10 low 
population was analyzed (Figure 8). For this population of cells, the intensity of Pax5.E6 
did not change significantly during LPS-activation, while the intensity of Pax5.E10 
expression increased throughout the activation period. Based on earlier findings, the 
increase in Pax5.E10 supports the idea that these cells are differentiating during 
activation. A second minor population Pax5.E6 low/Pax5.E10 high (predicted to be 
mature or activated B cells), also showed little change in intensity of exon 6- expression, 
while the intensity of E10 again increased throughout the activation period.
Together, these data demonstrate that in addition to increased cell frequency of 
E10 staining cells during activation, cells also exhibit a significant increase of Pax5 C- 
terminus intensity. This could be an indication that cells are not losing usage of exon 6 
expression as much as they are accumulating more Pax5 protein that contains a C- 
terminus.
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Figure 8. Change in relative intensity of Pax5.E6 and Pax5.E10 expression in LPS- 
activated SPL cells. Top graph: change in relative expression of the Pax5.E6 
high/Pax5.E10 low population. Bottom graph: change in relative expression o f the 
Pax5.E6 low/Pax5.E10 high population.
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Similarly, when experiments are performed using Pax5.E10 and Pax5.PD 
antibodies, the high co-staining population of cells upregulate Pax5.E10 expression as 
they reach terminal B cell differentiation, while levels of paired domain in the cell remain 
relatively constant during that period (Figure 9). Furthermore, Pax5.PD low/Pax5.E10 
high cells not only increase their Pax5.E10 intensity during activation, but 
simultaneously decrease their Pax5.PD intensity. This further emphasizes an increased 
role for the C-terminus and decreased role for the paired domain as early activated B cells 
differentiate toward antibody-secreting cells.
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Figure 9. Change in relative intensity o f Pax5.PD and Pax5.E10 expression in LPS- 
activated SPL cells. Top graph: change in relative expression of the Pax5.EPD 
high/Pax5.E10 low population. Bottom graph: change in relative expression of the 
Pax5.PD low/Pax5.E10 high population.
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Lastly, we analyzed changes in Pax5.PD/Pax5.E6 intensity during LPS activation 
(Figure 10). Upon LPS-activation, the main Pax5 population, which represents mature B 
cells (Pax5.PD high/Pax5.E6 int.), had increased intensity of both Pax5.PD and Pax5.E6 
domains. This increase in intensity corresponded with a transient increase in frequency of 
cells expressing high levels of both paired domain and exon 6 through day 4 of LPS 
activation. These patterns suggest that early activated B cells increase the amount of full- 
length Pax5 protein in their cells prior to downregulation of Pax5 during the final 
differentiation towards plasma cells.
The minor population of exon 6 possessing, but paired domain-lacking cells 
(Pax5.PD low/Pax5.E6 high) appears to lose even more Pax5.PD expression as the cells 
become more activated. Pax5.E6 expression per cell also decreases during activation. 
This population disappears over time, and consequently, this population could not be 
analyzed on day 7 after LPS activation. It is possible that this population represents T- 
plasma cells, which also have low expression of Pax5.PD [32]. Alternatively, a 
subpopulation of these E6 high cells is early developing cells because they co-stain with 
EBF and possibly develop into mature B cells during activation.
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Figure 10. Change in relative intensity of Pax5.PD and Pax5.E6 expression in LPS- 
activated SPL cells. Top graph: change in relative expression of the Pax5.EPD 
high/Pax5.E6 int. population. Bottom graph: change in relative expression of the 
Pax5.PD low/Pax5.E6 high population.
2.3.6. Expression of Pax5 subpopulations with HCmu during LPS-activation.
So far, our findings suggested that Pax5 isoforms lose their paired domain during 
B cell activation, while some of these cells maintain their Pax5 C-terminus. To further 
test the validity of these findings, we stained spleen cells with combinations of Pax5 
antibodies and the IgM-detecting (HCmu) antibody during LPS-activation, as presented
Pax5.E6
PaxS.PD
Pax5.E6
PaxS.PD
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in Figure 11. Figure 11A and 1 IB demonstrate unique flow cytometry patterns for 
Pax5.E6/HCmu expression and Pax5.E10/HCmu expression, respectively.
Figure 11. Two-color flow cytometry contours o f LPS-activated SPL cells stained with anti-Pax5 
and anti-HCmu antibodies. D: Day A) Cells stained with anti-Pax5.E6 and anti-HCmu antibodies 
across days in culture. B) Cells stained with Pax5.E10 and HCmu across days in culture.
The majority o f Pax5.E6 positive cells co-stained for the HCmu antibody, while 
Pax5.E10 positive cells split into a IgM-expressing (HCmu high) and IgM-lacking 
(HCmu low) population (Figure 1 IB). As the graphs demonstrate, both the Pax5.E6 
high/HCmu high population and the Pax5.E10 high/HCmu high population increase 
levels of HCmu per cell during the activation period, suggesting that cells expressing
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both Pax5 domains (E6 and E10) are activated B cells. It is unlikely that any of the high 
IgM-expressing (HCmu++) cells have differentiated into plasma cells by day 7 [16, 32], 
and this corresponds with continued expression of Pax5 up to that time point. However, 
EdU proliferation analyses reveal that some of these cells are plasmablasts that express 
all three Pax5 antibodies (data not shown).
Two interesting additional observations can be made: first, when staining with 
Pax5.E10, there is a very significant shift from most cells being HCmu+ and Pax5.E10 
double-positive cells, to almost equal numbers of IgM+ and IgM- cells that all contain the 
C-terminus of their Pax5 protein. Although some these IgM- cells additionally express 
the paired domain (data not shown), the frequency of the Pax5.E10+/IgM- population is 
consistently higher than the Pax5.PD/IgM- population. This further supports an important 
role for exon 10 during terminal B cell differentiation.
A second observation is that a minor, high Pax5.E6/low HCmu staining 
population is downregulated during B cell activation and is undetectable by D7. This is 
likely the same population observed earlier, Pax5.PD low/Pax5.E6 high (Figure 7).
Hence, during terminal B cell differentiation, a population of paired domain-lacking, 
exon 6 expressing, but IgM-lacking B cells, (PD-/E6+/Hcmu-) disappears. It is possible 
that this population represents one of the two early developing B cell populations (PD- 
/E6+/E10+ or PD-/E6+/E10-) described above.
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Table 3. Average % frequency (S.E.) of LPS activated SPL cells.
Pax5.E6/Pax5.E10 Q1 (E6+/E10-) Q2 (E6+/E10+) Q3 (E6-/E10-) Q4 (E6-/E10+)
DO 1.0 (0.3) 52.7(11.5) 37.9 (12.1) 8.4(1.6)
D2 1.5 (0.9) 44.9 (2.0) 44.6 (2.5) 9.1 (1.5)
D4 1.3 (0.9) 39.0(5.3) 44.8 (12.0) 14.9 (7.3)
D7 2.5 (1.1) 21.0 (0.9) 56.5 (7.3) 20.0 (9.3)
Pax5.PD/Pax5.E10 Q1 Q2 Q3 Q4
DO 0.3 (0.1) 51.0 (5.4) 34.1 (8.1) 14.6 (4.0)
D2 0.1 (0.0) 39.6(1.3) 40.7 (2.5) 19.6(3.3) '
D4 0.0(0.0) 33.9 (4.6) 42.0 (1.2) 23.8 (5.6)
D7 0.1 (0.0) 13.0 (0.8) 56.2 (12.3) 30.7(13.0)
Pax5.PD/Pax5.E6 Q1 Q2 Q3 Q4
DO 27.7(5.1) 21.9 (4.3) 48.4 (1.5) 2.0 (0.3)
D2 14.9 (5.6) 23.1(3.7) 60.1 (5.0) 2.0 (0.5)
D4 6.4 (1.8) 27.3 (5.3) 64.3 (6.0) 1.9 (0.6)
D7 2.6 (0.4) 11.8 (3.3) 83.0 (3.7) 2.6 (1.0)
HCmu/Pax5.E6 Q1 Q2 Q3 Q4
DO 2.7 (1.3) 36.1(3.8) 48.7 (3.6) 12.5(2.6)
D2 1.2 (0.6) 33.2 (4.7) 57.0 (6.3) 8.6 (2.8)
D4 1.4 (0.8) 33.1 (4.3) 57.1(5.6) 8.4 (2.7)
D7 5.5 (3.1) 18.7(4.1) 68.8(6.7) 7.0 (2.1)
HCmu/Pax5.E10 Q1 Q2 Q3 Q4
DO 1.7 (0.4) 39.3 (4.4) 38.9 (4.9) 20.1(1.0)
D2 0.5 (0.1) 30.5 (3.7) 53.5 (6.4) 15.5 (2.9)
D4 2.6 (0.7) 30.1 (4.7) 56.2 (5.1) 11.1 (1.2)
D7 8.5 (1.9) 9.4(2.8) 74.4 (6.8) 7.8 (2.2)
Note. D: day fixed after LPS activation.
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2.3.7. Comparative expression of Pax5 subpopulations in the mouse and rainbow trout.
Much of the previous work on Pax5 alternative splicing has been performed using 
murine models. To further test our findings in the teleost model and to elucidate 
important evolutionary differences between teleosts and mammals, we performed two- 
color flow cytometry on freshly isolated mouse bone marrow (the functional equivalent 
to the anterior kidney) and mouse spleen cells. Cells were stained with a mouse 
equivalent of anti-Pax5.E10 antibody (C20) and the conserved anti-Pax5.PD antibody 
(ED-1). We do not currently have a mouse equivalent of the Pax5.E6 marker and 
therefore cannot use this for comparison. Elowever, to further ascertain the identity of 
early developing, Pax5-expressing-B cell subpopulations, cells were stained with anti- 
EBF and anti-HCmu in combination with Pax5 antibodies.
Based on our findings in trout, we predicted that the mouse bone marrow would 
possess an early developing subpopulation with the Pax5 pattern PD -/E 10+/HCmu- 
/EBF+. To test this prediction, we first stained mouse bone marrow cells for Pax5.PD and 
Pax5.E10. Figure 12 demonstrates that the flow cytometry patterns for bone marrow cells 
stained with this combination are different from the patterns identified earlier for trout 
anterior kidney cells. In contrast to anterior kidney, the bone marrow maintains a high 
frequency (27.0%) o f cells lacking the paired domain (Pax5.PD negative) but expressing 
the Pax5 C-terminus (Pax5.E10 high cells). As presented earlier, the anterior kidney 
maintains a high frequency (20.3%) of cells expressing the paired domain but with low 
C-terminus expression. Previous research demonstrates that murine bone marrow consists 
o f more early developing B cells and fewer late developing B cells than the trout anterior
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kidney [32]. 
attributed to
M ouse
Trout
The higher frequency of the Pax5 C-terminus expressing cells may be 
the fact that mouse bone marrow contains more early developing B cells.
«*
-> PaxB.ElO
Figure 12. Two-color flow cytometry o f mouse bone marrow (BM) and spleen (SPL) 
cells, and trout antierior kidney (AK) and spleen (SPL) cells stained with anti-Pax5.PD 
and anti-Pax5.E10 antibodies.
Surprisingly, when the PD/E10 combination in mouse spleen was tested, a small 
population of larger (high FSC) cells expressing the Pax5 C-terminus, but not the paired 
domain was identified. This population is similar to the small PD-/E10+ population 
identified in trout spleen. While the frequency o f the mouse spleen Pax5.E10 high 
population is 0.9%, the trout spleen Pax5.PD low/Pax5.E10 high subpopulation is 16.4%.
67
The difference in frequencies may be explained by the earlier finding that trout spleen 
consists of a Pax5.E10 high mature/activated B cell population in addition to a Pax5.E10 
high early developing B cell population.
M o u s e  BM M o u s e  SPL
4.0%CO
* 0’ S O *  1
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Figure 13. Two-color flow cytometry contour graphs for mouse and trout immune tissues. 
A) Mouse bone marrow (BM) and spleen (SPL) using anti-EBF and anti-Pax5.E10 
antibodies. B) Trout anterior kidney (AK) and SPL using anti-EBF and anti-Pax5.E10 
antibodies.
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To test whether mouse Pax5.E10 high populations represented early developing B 
cells, we stained mouse cells with a combination of the anti-EBF and anti-Pax5.E10 
antibodies. Remarkably, in both mouse bone marrow and spleen, the Pax5.E10 high/EBF 
high populations co-stained EBF and exemplified flow cytometry patterns comparable to 
the trout anterior kidney and spleen (Figure 13). In mouse spleen, the frequency of the 
Pax5.E10 high population was 2-4%. In comparison, in trout spleen we had observed two 
EBF high populations that co-stained with Pax5.E10, one at 2.9% and one at 2.0%. 
Together with the previous data, these patterns suggest that both species have a 
population of early developing B cells that express their Pax5 C-terminus, but do not 
express the paired domain (Figure 12). Furthermore, in mouse as in trout, the Pax5.E10 
high/EBF high population does not co-express FICmu (data not shown). From these 
findings, we can conclude that although mouse and trout may differentially utilize 
isoforms containing the C-terminus during B cell maturation and activation, both species 
possess an isoform containing exon 10, but lacking paired domain, during early B cell 
development.
2.3.8. Concluding Remarks.
In conclusion, we have demonstrated that antibodies targeting three distinct 
domains o f Pax5 can be used with flow cytometry to identify individual B cell 
populations in rainbow trout using flow cytometric analysis. Early developing B cells, 
and potentially common lymphocyte progenitors, lack the paired domain and are 
characterized by high exon 6 expression. Early pro-B cells may similarly have high exon
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6 expression, but are further characterized by high exon 10 expression. These cell 
populations are observed in both the anterior kidney and the spleen.
The majority of mature B cells expressed in the spleen are characterized by full 
length Pax5 expression. However, there is an additional population of mature/activated B 
cells that are low in Pax5 paired domain and high in Pax5 C-terminus. By staining LPS 
activated cells, we have demonstrated that terminal differentiation is characterized by the 
loss of the paired domain and potential maintenance or increase of the C-terminus. 
Additionally, we have shown that activated B cells, there is a transiently increase in the 
expression of full length Pax5 expression. Finally, using a murine model, we have 
provided support for our novel finding that Pax5 isoforms lacking the paired domain are 
observed in early developing B cell populations. Furthermore, we have demonstrated that 
the use o f these isoforms in developing B cells is potentially conserved between 
mammalian and teleost species.
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Chapter 3- R and S Fish
3.1 Introduction.
Flavobacterium psychrophilum  is the pathogen responsible for bacterial cold 
water disease (BCWD), a sickness which contributes to high mortality rates in 
aquaculture [93]. Recent work at the National Center for Cool and Cold Water 
Aquaculture has attempted to identify traits of rainbow trout resistant to BCWD and to 
selectively breed resistant trout through three generations [94]. The selection process has 
proved promising, but it has yet to be uncovered which molecular mechanisms underlie 
trout flavobacterium resistance. One potential mechanism contributing to resistance is a 
change in humoral immune response. Therefore, to investigate the humoral immunity of 
resistant trout, our lab is currently utilizing flow cytometry to compare and contrast the B 
cell populations composing the resistant and susceptible trout immune tissues. In this 
chapter, we present key preliminary results regarding the proliferating, developing, and 
activated B cell populations.
3.2 Results.
To further understand the molecular basis of bacterial cold water disease 
resistance, our lab examined B cell development and activation in trout bred to be 
genetically resistant (R line) or susceptible (S line) to flavobacterium. We first created 
single cell suspensions from either freshly isolated R line or S line trout immune tissues. 
We then fixed, permeabilized, and stained cells with antibodies targeting developmental 
transcription factors and HCmu. We additionally performed primary cell culturing of
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cells in the presence of mitogen LPS and proliferation marker EdU prior to cell fixation. 
Two-color flow cytometry was performed to analyze differences in cell proliferation and 
B cell development and activation.
3.2.1 Differences in LPS activated B cell proliferation.
To test the differences in B cell proliferation, R line and S line trout blood and 
spleen were LPS activated over seven days. Prior to collection, cells were cultured in the 
presence o f nucleoside analog EdU (Invitrogen). The cells were then fixed, 
permeabilized, and stained with either the anti-Pax5.E10 or Pax5.E6 antibodies (for 
methods, see Chapter 2).
As expected, the majority of proliferating blood and spleen cells expressed both 
exon 6 and exon 10 of Pax5, suggesting these cells were in the plasmablast stage of 
activation (see Q2 of Tables 4 and 5). The preliminary results do not suggest a trend in 
the frequency of proliferating B cells expressing Pax5.E10 versus the frequency of 
proliferating cells expressing Pax5.E6. However, observations from one experiment may 
suggest that more proliferating cells are Pax5.E10 negative across activation than 
Pax5.E6 negative. This means that as B cells terminally differentiate, they lose isoforms 
containing exon 10 of Pax5. Although Pax5.E10 is maintained in a higher frequency of 
cells during activation than Pax5.E6, it could be the case that only Pax5.E6 is expressed 
later in the transient plasma cell stage.
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Table 4. Average frequency of proliferating and non-proliferating Pax5.E10 cells (S.E.).
R-
PBL
D2 D4 D7
S-PBL
D2 D4 D7
R-
SPL
D2 D4 D7
S-SPL
D2 D4 D7
Q1
E10+/EdU-
19.3
(7.9)
38.5
(9.0)
46.2
(11.7)
23.9
(10.9)
38.9
(9.3)
41.1
(14.7)
34.4
(9.0)
28.7
(5.4)
18.1
(3.1)
50.3
(10.4)
47.4
(9.2)
27.2
(5.1)
Q2 0.3 1.7 0.7 0.2 3.7 2.6 0.2 1.2 0.4 0.3 1.1 0.7
E10+/EdU+ (0.2) (0.4) (0.4) (0.0) (1.2) (1-3) (0.1) (0.5) (0.2) (0.0) (0.5) (0.3)
Q3
E10-/Edll-
80.1
(7.7
59.3
(8.7)
53.0
(11.3)
75.8
(11.0)
56.7
(10.0)
54.8
(13.4)
65.4
(8.9)
69.8
(4.8)
81.4
(3.3)
49.4
(10.4)
51.1
(9.5)
71.9
(5.20
Q4
E10-/EdU+
0.3
(0.2)
0.5
(0.3)
0.0
(0.0)
0.1
(0.0)
0.7
(0.5)
1.4
(1.3)
0.1
(0.0)
0.3
(0.2)
0.0
(0.0)
0.0
(0.0)
0.3
(0.2)
0.2
(0.2)
Note. S.E. represented in parentheses. D: Day of fixation after LPS activation
Table 5. Average frequency of proliferating and non-proliferating Pax5.E6 cells (S.E.).
R-PBL S- PBL R-SPL S-SPL
D2 D4 D7 D2 D4 D7 D2 D4 D7 D2 D4 D7
Q.1
E6+/EdU-
33.31
(11.4)
42.0
(12.1)
47.7
(4.6)
32.8
(6.9)
38.3
(10.4)
49.5
(8.7)
40.4
(10.3)
32.9
(6.6)
25.9
(7.3)
43.0
(10.1)
39.7
(7.0)
31.9
(3.8)
Q2
E6+/EdU+
0.1
(0.0)
0.4
(0-2)
0.1
(0.0)
0.1
(0.0)
2.1
(2.4)
1.2
(0.7)
0.2
(0.0)
0.7
(0.3)
0.3
(0.2)
0.2
(0.0)
0.8
(0.3)
0.5
(0.3)
Q3
E6-/EdU-
66.6
(11.4)
57.5
(12.2)
52.1
(4.6)
67.1
(6.9)
48.7
(12.6)
49.3
(9.4)
59.3
(11.8)
66.4
(6.3)
73.8
(7.4)
56.7
(10.1)
59.5
(6.8)
67.5
(3.6)
Q4
E6-/EdU+
0.0
(0.0)
0.1
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.1)
0.1
(0.1)
0.0
(0.0)
0.0
(0.0)
0.1
(0.0)
0.1
(0.1)
Note. S.E. represented in parentheses. D: Day of fixation after LPS activation
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Total proliferation of cells independent of Pax5 expression was also identified for 
each experiment. The results show that blood had the highest proliferation and expressed 
proliferating cells differently between resistant and susceptible lines of trout. The 
frequency of proliferating cells during activation is higher in the S line blood versus the R 
line blood (Figure 14A). In contrast to blood, there was very little cell proliferation in the 
spleen and there appeared to be no differences in spleen cell proliferation between the R 
line and S line (Figure 14B). These findings were unexpected due to initial observations 
during our earlier experiments with younger trout. In these first experiments, we observed 
greater increases in cell proliferation in blood and spleen of the R line compared to the S 
line. However, in later experiments with older fish, we observed the opposite for blood 
and the lack of proliferation in spleen cells. One possible explanation for this change 
could be that the older resistant fish contained more erythrocytes than susceptible fish.
The increased presence o f erythrocytes in these R line spleens could possibly alter the 
ability o f cultured lymphocytes to uptake the EdU. A consequence of this would be a 
false negative proliferation result. However, it is still possible that earlier experiments 
were outliers. A larger sample size will be necessary before any conclusions can be 
drawn for these proliferation studies.
3.2.2 Differences in B cell development.
Our initial study of Pax5 isoform expression in B lymphocytes revealed a 
population of early developing B cells lacking the Pax5 paired domain but expressing 
Pax5 exon 6. This population was found (at different frequencies) in the anterior kidney,
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blood, and spleen. The presence o f this developing population in both primary and 
secondary immune tissues lead us to believe it would be an interesting candidate 
population to compare between R and S lines of trout. We therefore analyzed the 
frequency of cells in the Pax5.PD low/Pax5.E6 high population across tissues. By using 
this combination, we ensured that we were examining an early developing Pax5 
population lacking in paired domain. The results show an interesting trend: the 
developing population is present at a higher frequency in R line anterior kidney and blood 
compared to S line (Figure 15A). Conversely, in spleen, the developing population has a 
higher frequency in the S line than the R line.
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DO D2 D4 D7
Figure 14. The average frequency o f proliferating cells in R line and S line blood (A) and spleen 
(B).
There are several potential explanations for the differences in developing B cell 
populations. Previous studies demonstrated increases in murine spleen hematopoiesis at 
the expense of bone marrow hematopoiesis after viral or bacterial infection [95-97]. It is 
possible that infection in rainbow trout induces a response resulting in increased splenic 
B cell development. In contrast to spleen, the increase in developing B cells in the 
anterior kidney and blood o f resistant fish could provide a means to protect against
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infection. If this is true, then this follows our expectation that susceptible fish have a 
lower frequency o f developing B cell populations in the anterior kidney and blood. 
However, this is again speculation; larger sample sizes and statistical analysis will reveal 
if these findings reflect a true biological phenomenon.
B
Figure 15. Differences in early developing (A) and activated (B) B cell populations in R 
and S lines of trout.
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3.2.3. Differences in blood B cell activation.
Using three-color flow cytometry, we previously demonstrated that a population 
of blood cells expressing high paired domain (Pax5.PD) and Pax5 exon 6 (Pax5.E6) were 
additionally high in HCmu expression. The HCmu expression indicated this population 
was highly activated. Interestingly, this population had the highest frequency in the 
blood, suggesting a role for more activated B cells in this tissue. Therefore, we decided to 
investigate changes in this activated population between R and S line blood using two- 
color flow cytometry for Pax5.PD and Pax5.E6 expression. The results demonstrate a 
slight increase in the frequency of the activated population in resistant fish (Figure 15B). 
An increase in activated cells could be a mechanism allowing the fish to have B cells 
more readily available to fight pathogen. However, this result does not likely represent a 
statistically significant finding as the standard error was large in both resistant and 
susceptible fish samples. Therefore, in our preliminary experiments there appears to be 
no difference in the Pax5.PD/Pax5.E6 population between trout strains. However, as the 
blood is a highly variable tissue and our sample size is small, it may be premature to 
conclude no differences exist.
3.2.4. Concluding remarks.
Our preliminary results suggest two major differences in B cell populations 
between R and S lines of trout. First, the susceptible fish may express a higher frequency 
of proliferating blood plasmablasts after day four of LPS activation, as demonstrated by 
cells’ combinatorial expressions of Pax5.E10 (or Pax5.E6) and EdU. The reason for
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higher proliferation in susceptible trout is unclear, but one potential explanation could be 
that the fish are inducing a greater humoral response to pathogen more frequently than 
the resistant fish. Our preliminary data also suggest a role for early developing B cells in 
anterior kidney and blood (but not spleen) in resistant line trout. With a higher frequency 
of early developing B cells, resistant fish may be able to more readily fight pathogen by 
inducing a more rapid developmental program.
Although no differences were identified when examining the activated 
Pax5.PD/Pax.E6 high B cell population, our observations indicate there still may be 
differences in activated B cells between fish strains. The data from other Pax5 
combinations in addition to LPS studies suggest resistant fish more often express higher 
frequencies o f cells in many o f the activated B cell populations (data not shown). The 
spleen will be a particularly interesting tissue to examine in this context and other studies 
of resistant fish have already demonstrated that spleen sizes, particularly larger spleens, 
correspond to flavobacterium resistance [98]. Overall, the potential to identify differences 
in developing B cell populations between resistant and susceptible trout is promising. 
Identifying the molecular context o f flavobacterium resistance is essential for 
understanding the implications of genetic alterations and is invaluable knowledge for 
future aquaculture engineering.
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Chapter 4-Discussion.
The expression and function of Pax5 isoforms remains an enigma in the 
immunological community. Thus far, the use of RT-PCR has enabled researchers to 
identify multiple transcripts that encode N- and C-terminal Pax5 isoforms, many of 
which are conserved across species. Such studies have revealed that trout, mice, humans, 
and amphioxus all express a subset of Pax5 isoforms that lack either the paired domain or 
C-terminus. Transfection studies have further demonstrated these isoforms are not only 
translated, but also have functional transactivating capabilities. Despite these advances, 
research has yet to demonstrate a definitive pattern of Pax5 isoforms across cell lines, 
immune tissues, and malignancies. Furthermore, investigators still do not understand the 
biological function of these distinct isoforms or the relevance o f their expression patterns. 
Here, for the first time, we support a role for Pax5 isoforms by demonstrating differential 
isoform expression in individual developing and activated B cell populations in rainbow 
trout. Although our flow cytometric approach has limitations, it reveals that distinct early 
developing and activated populations can be characterized by their combined expression 
o f transcription factors, surface markers, and Pax5 domains. Collectively, we call this 
expression pattern the “Pax5 signature” of a tissue.
4.1 The Pax5 patterns of early developing B cells.
The anterior kidney is a complex immune tissue composed of early developing, 
late developing, and long-lived plasma cells ([2, 3, 32, 76]. Previous studies have 
separated anterior kidney populations by their diverse expression of EBF, HCmu and
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most relevantly, the Pax5 paired domain [32]. The majority of early developing B cells 
are characterized by high FSC, high EBF expression, and low Pax5 paired domain 
expression [32]. As the paired domain is essential for the transcription of genes 
necessary for B cell fate [8, 60], it is remarkable that our results identified a large 
population of the earliest developing B cells, including potential CLPs, that express 
isoforms of Pax5 that contain exon 6 but lack both the paired domain and the C- 
terminus. These cells have a Pax5 pattern PD-/E6+/E10- with a B cell signature PD- 
/E6+/E10-/HCmu-/Xbpl+/EBF+. This high FSC population consistently co-stained high 
levels o f Xbpl and EBF, and remained negative in heavy chain immunoglobulin 
expression, suggesting it constituted the earliest of B cell populations (see Table 1).
Most importantly, the earliest B cell population suggests a conserved 
developmental role for Pax5 isoforms lacking exon 2 and exon 10. In general, one 
proposed function for differential isoform expression is to regulate the activity of full 
length proteins by competing with full length isoforms for protein/DNA binding partners. 
This mechanism has been observed for isoforms of the alternatively spliced transcription 
factor Ikaros (reviewed in [99]). Supporting this hypothesis, studies o f murine Pax5 show 
that the Pax5-d isoform may act as a dominant negative regulator; when co-transfected 
with full length Pax5 in vitro, it downregulates the activity of the full length protein [84]. 
Cross-species analyses reveal vast differences in Pax5 isoform expression; however, 
almost all species examined share isoforms lacking a functional paired domain. Recent 
research suggests that although Pax5 isoforms lacking a paired domain are incapable of 
binding DNA, they may still indirectly regulate transcription at anti-sense promoters via
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the Pax5 partial homeodomain located on exon 6 [100]. Research has yet to elucidate if 
this mechanism of regulation is prominent in early developing B cells.
The lack o f exon 10 expression in the earliest developing B cells demonstrates 
that in addition to a lack of DNA binding capability, early B cells also lack a repressor 
domain. Although the function o f the repressor domain remains poorly understood, 
studies demonstrate that deletion of the last 22-33 amino acids of the Pax5 C-terminus 
results in increased Pax5 transactivating potential. Thus, the Pax5 transactivation domain 
may be strongly regulated by this adjacent inhibitory domain [71]. The lack of this 
domain in early developing cells suggests a potential role for this inhibitory domain in B 
cell activation, a hypothesis which is addressed later in this discussion.
An additional subpopulation of cells lacking the paired domain but possessing 
regions encoded by both exons 6 and 10 further supports a role for paired-domain-lacking 
isoforms in development. This population had a Pax5 pattern PD-/E6+/E10+ and a B cell 
signature PD-/E6+/E10+/HCmu-/Xbpl+/EBF+. Elowever, these cells expressed lower 
levels of Xbpl as compared to the earliest developing B cells, suggesting that they have 
progressed to a later stage of B cell development.
The role of cells lacking the Pax5 paired domain but expressing the Pax5 C- 
terminus in development was further evidenced by our murine model. Mouse bone 
marrow cells displayed similar patterns to the trout anterior kidney cells; the bone 
marrow had a population of cells that lacked the Pax5 paired domain but co-expressed 
EBF and the Pax5 C-terminus. As we do not currently have an equivalent antibody for 
the exon 6 domain of murine Pax5, we do not know whether bone marrow cells express
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isoforms with the Pax5 C-terminus solely in progenitor B cells or if earlier developing 
cells also express isoforms with the C-terminus. In the anterior kidney, the majority of 
early developing cells expressed both exon 6 and exon 10 of Pax5, suggesting these two 
exons are expressed on similar isoforms.
The anterior kidney represents the primary site of hematopoiesis [3]. However, 
our results demonstrated that trout spleen also houses a population of early developing 
cells. Currently, there are no available surface markers, such as CD43 and CD34, to 
identify trout hematopoietic cells, but our findings suggest that hematopoiesis occurs in 
this secondary immune tissue. While this discovery of early developing cells in spleen is 
the first report of such a population in teleosts, it reflects similar findings in mammals 
which have demonstrated human and porcine hematopoiesis occurring in the adult spleen 
[101]. Importantly, we show that in both mouse and trout spleen, these early developing 
B cells lack the paired domain and express the Pax5 repressor domain (E10), further 
supporting a role for Pax5 isoforms lacking the paired domain in development.
4.2 The Pax5 patterns of late developing B cells
Late developing B cells o f the anterior kidney include the small pre-B, immature, 
and mature B cells [32]. These cells have previously been characterized as having high 
Pax5 expression, HCmu expression, and low FSC. This trend was further supported by 
our data. In the anterior kidney, we consistently observed a population of cells expressing 
paired domain isoforms that were low in FSC (Figure 11). What is interesting about this 
population of developing B cells is that they had higher paired domain expression than
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exon 6 and exon 10 expression. This late developing population is composed of 
approximately 20-30% lymphocytes, consistent with previous findings that late 
developing cells expressing Pax5 constitute approximately 18.2% of the anterior kidney 
[32]. The higher expression of the Pax5 paired domain in these late developing cells 
suggests there is an upregulation of isoforms expressing the paired domain (including full 
length Pax5) as early as the pre-B stage of development. An additional subpopulation of 
these late developing cells co-stained all three Pax5 isoforms and presumably expresses 
full length Pax5. Although similar patterns are observed in trout and mouse, it should be 
noted that we do not observe the same degree of co-staining in murine bone marrow. 
Consistent with earlier studies from our lab [32] one possible explanation for this is that 
the trout anterior kidney consists of more late-developing B cells (18.2%) than murine 
bone marrow (13.4%).
4.3 The Pax5 patterns o f activated and differentiating B cells.
A great majority of lymphocytes in the trout spleen (and presumably blood) are 
either mature or activated B cells [2, 16]. Such cells co-expressed each of the three tested 
Pax5 domains, suggesting that mature B cells express the full length Pax5. A 
subpopulation of mature B cells upregulated its Pax5 C-terminus expression but not its 
paired domain expression. These cells were larger than resting B cells and were possibly 
partially activated B cells. This notion is supported by the LPS data, which demonstrates 
that, in activated B cells, C-terminus expression per cell is upregulated while the paired 
domain expression per cell remains constant. When mature B cells were LPS activated,
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we observed a relative increase in expression for all three Pax5 domains, suggesting that 
the full length isoform is upregulated upon initial activation of mature B cells. Murine 
splenocytes also upregulate Pax5 upon initial activation, as demonstrated by increases in 
Pax5 RNA expression [82]. This is the first time a similar trend has been observed for 
Pax5 protein in trout using flow cytometry.
The role of the C-terminus in Pax5 function remains largely unknown, with the 
exception that it contains an inhibitory domain adjacent to an upstream transactivation 
domain [71]. In mice, deletion of the last 22-33 amino acids of the C-terminus results in 
increased Pax5 transactivating potential, suggesting that the Pax5 transactivation domain 
is strongly regulated by the adjacent inhibitory domain [71]. However, the loss of the C- 
terminus does not affect the ability o f Groucho family members to repress Pax5 
transactivation of target protein [70]. Thus, it is difficult to establish how maintenance o f 
the C-terminus (as opposed to the maintenance of the paired domain) is important for 
Pax5 function during LPS activation.
There are several further pieces of evidence from our lab that B cell activation by 
LPS, results in an increase in the frequency of cells lacking a paired domain. First, using 
RT-PCR and primers targeting the full length Pax5 isoform and isoforms lacking exon2 
(paired domain) in LPS activated spleen cells, we identified an increase in the ratio of 
paired domain-less isoforms to paired domain containing isoforms across days of 
activation (Bruce and Zwollo, unpublished data). Furthermore, we were able to correlate 
this with an increased ratio o f secreted IgM to membrane IgM. Together, these results
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suggest that as cells are activated and differentiate into antibody-secreting plasma cells, 
they are expressing more isoforms lacking the paired domain.
In addition to this in vitro approach examining isoform expression, our lab has 
also observed in vivo changes in isoform expression using spawning O. nerka samples 
(Bruce, Clister, Epp, Schouten, and Zwollo, unpublished results). Spawning fish are 
known to have increased immune activation. Using RT-PCR, our lab has observed an 
increase in the ratio of exon 2 lacking isoforms to exon 2 containing isoforms in these 
spawning fish relative to non-spawning trout controls. Furthermore, this ratio correlates 
with an increased ratio of secreted to membrane IgM. Together, these findings correlate 
with findings of the present study which demonstrate that during terminal B cell 
differentiation, activated B cells will shift towards the paired domain lacking forms of 
Pax5.
4.4 The Pax5 patterns o f peripheral blood.
The peripheral blood is a highly variable and dynamically changing population, 
potentially harboring resting, mature B cells while transporting activated and long-lived 
plasma cells to their destinations [3, 76]. Our results demonstrate that in addition to 
mature and activated B cells, the blood also potentially contains early developing B cells. 
These cells lack Pax5 paired domain expression yet still express high levels of protein 
expressing exon 6 (Figure 11). We have not yet tested if this population co-stains the 
early B cell marker EBF, but it does exhibit high Xbpl expression (Figure 12) and RAG 
(an early developmental marker similar to EBF), suggesting it truly represents early
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developing cells (Barr and Zwollo, unpublished). Additionally, the blood also contained a 
population of cells that were low in paired domain and exon 6 expression, yet consisting 
of the Pax5 exon 10. It is possible that these cells represent the population of early 
activated B cells described earlier. However, due to the variability in blood, it is difficult 
to truly ascertain the identity of these populations, a point discussed further in the 
limitations of this study.
4.5 Pax5 isoform model.
Our initial hypothesis proposed that Pax5 isoform expression modulates the 
activity of Pax5 to affect B cell development and activation. We predicted that specific 
isoforms would be present in both developing and activated B cell populations and that 
the presence or absence of a particular isoform would either result in the progression or 
inhibition of the B cell developmental pathway (see Chap. 1, Figure 1.6). Although we do 
not yet know the function of individual isoforms, we have discovered that particular B 
cell stages are characterized by the expression of specific Pax5 protein domains (Figure 
16). Our preliminary model suggested that isoforms containing the Pax5 paired domain 
would drive B cell development and that those isoforms lacking the paired domain would 
inhibit it. Our current model (Figure 16) supports this prediction; the paired domain is 
progressively turned on throughout early B cell development, starting at the pre-B cell 
stage, and remains part o f Pax5 until the plasmablast stage. However, isoforms lacking in 
paired domain expression, including isoforms containing the repressor domain and exon 
6 domain, may already be present at the earliest stages of B cell development including
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the common lymphocyte progenitor stage. Importantly, in contrast to our original model 
(Chap. 1 Figure 1.6), Pax5 isoforms containing the C-terminal repressor domain may be 
necessary to promote B cell development rather than inhibit it. This model is supported 
by our observation that C-terminal containing isoforms are present during the pro-B cell 
stage o f Pax5 (Figure 16).
Our preliminary model further suggested that the C-terminus was necessary for B 
cell terminal B cell differentiation and that the absence of the repressor domain would 
inhibit this process. The TPS activation experiments support this hypothesis. The 
frequency of mature and activated cells expressing the C-terminus increased throughout 
activation, as did the relative number o f Pax5.E10 positive iso forms per cell. In contrast, 
the frequency of these cells expressing the paired domain decreased and additionally, the 
number of isoforms per cell expressing Pax5.PD remained constant. This supports the 
prediction that the isoforms lacking the paired domain are necessary for terminal B cell 
differentiation, while isoforms containing the repressor domain keep their function even 
later in the terminal differentiation process, possibly until the transitional plasma cell 
stage.
Our results also suggest that specific Pax5 isoforms may characterize other 
possible novel B cell populations, such as phagocytic B cells (Li et al., 2006) or memory 
B cells (Ye et al., 2011). In this study, we identified an interesting population of cells low 
in Pax5 paired domain expression, high in Pax5 C-terminus expression, and lacking 
HCmu expression. We propose that this population may represent phagocytic B cells 
lacking in IgM expression. As the current literature has not examined Pax5 expression in
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phagocytic B cells, this possibility should be addressed in future studies (see later 
section).
4.6 Pax5 signatures.
By characterizing the B cell populations of a tissue through their flow cytometric 
patterns of Pax5 domain expression and delineating the frequencies of these B cell 
populations, we can create a Pax5 signature for each unique immune tissue. The Pax5 
signature of a tissue is a means by which researchers can identify aberrant molecular 
expression via changes in the frequencies of key B cell populations. The Pax5 signature 
can be used to compare immune tissues across species or to compare different tissues 
within a species (i.e. anterior kidney and blood). It can also be used in diagnostics by 
comparing the Pax5 signature of a tissue exposed to pathogen versus a control (as 
demonstrated in the next section), or by examining a malignant tissue compared to a 
healthy tissue. As research further elucidates the patterns of Pax5 isoform expression in 
developing B cell populations, the more these patterns can be applied to examine immune 
tissues as a whole. The ability to apply a Pax5 signature to immune tissues will be 
beneficial to both future comparative and clinical immunology studies.
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4.7 Flavobacterium resistant versus susceptible fish.
Bacterial cold water disease (CWBD) is prevalent in aquaculture and is 
responsible for high mortality rates in salmonid species [93]. Understanding the 
molecular mechanisms underlying fish resistance to this disease will better equip the 
aquaculture industry to prevent disease. Our preliminary results demonstrate that 
changes in B cell development and the humoral response may contribute to the 
mechanisms leading to flavobacterium resistance. Our data showed a higher frequency of 
early developing B cell populations in the anterior kidney and blood of fish resistant to 
CWBD compared to susceptible fish. Although more experiments are required to 
determine if these changes are statistically significant, the early developing B cell 
population (containing exon 6 of Pax5) remains an excellent candidate population to 
study as it is present in all immune tissues. Additionally, preliminary observations of this 
same population in the anterior kidney of splenectomized trout demonstrate it is a 
dynamic population: there is a lower frequency of exon 6 expressing B cells in 
splenectomized trout anterior kidney compared to control trout (Zwollo, unpublished 
data). This suggests that the early developing B cell population responds to atypical 
changes in the immune tissues as it needs mature cell to replace those mature B cells lost 
from the splenectomy. It supports preliminary evidence that higher frequencies of early 
developing B cell populations may be characteristic of fish resistant to infection.
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4.8 Limitations to the current study.
The current flow cytometric approach enabled us to demarcate novel B cell 
populations in rainbow trout and to demonstrate that these populations differ in their 
patterns o f Pax5 domain expression. However, there are populations in the current study 
that remain elusive without the availability of further immunological markers. One such 
population is the Pax5 positive populations that lack IgM HCmu expression. 
Approximately 15-20% of gated lymphocytes constituted this population in spleen 
(Figure 10) and the population was additionally observed in anterior kidney and blood 
(data not shown). This same population has previously been reported by our lab [32, 76]. 
Recent research has identified the presence of phagocytic B cells and B-l cells in trout 
[102, 103]. However, each of these studies utilizes IgM as a B cell marker. So far, no 
research has examined Pax5 expression in phagocytic B cells. It is possible that our 
population o f cells expressing Pax5 but lacking in IgM constitutes some of the IgM 
lacking phagocytic B cells. Alternatively, these cells could represent an early developing 
B cell population; however, this is unlikely as these cells did not co-stain for EBF. 
Additional experiments to test the phagocytic hypothesis are presented in the next 
section.
The flow cytometric patterns o f Pax5 subpopulations were remarkably consistent 
across experiments. Although we were able to utilize these patterns to identify individual 
B cell populations, it remains formally plausible that observed patterns are not a 
reflection of alternative splicing events. Instead, because multiple regulatory proteins 
interact with Pax5 to modify transcription throughout B cell development, it is formally
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possible that protein-protein interactions block available Pax5 sites for antibody binding 
in the context of flow cytometry experiments. .
Although protein-protein interactions may account for our findings, independent 
data from Western blots using the three anti-Pax5 antibodies (Figure 2) supports that 
alternative splicing is responsible for the observed flow cytometric patterns. Notably, 
these blots reveal that anterior kidney contains less of the paired domain containing 
isoforms at the molecular weight for full length Pax5, suggesting that full length Pax5 is 
not expressed as frequently in this tissue. Furthermore, the full length Pax5 protein is 
found in both trout blood and spleen, consistent with our finding that mature and 
activated B cells contain full length Pax5. The blots additionally reveal that the Pax5.E10 
antibody recognizes both full length Pax5 and an additional isoform of smaller molecular 
weight in blood and spleen. This matches the high frequency of a Pax5.E10 population 
that lacks the Pax5 paired domain in these tissues. Finally, the blots demonstrate that 
Pax5.E6 is found consistently across tissues, thus matching the flow cytometry data.
Western blot analysis reveals the complexity of Pax5 patterns occurring across 
immune tissues and demonstrates that examining protein expression as a collective sum 
of the entire immune tissue protein expression leads to a poor understanding of Pax5 
protein function. Our flow cytometric approach in conjunction with Pax5 antibody 
staining remedies this problem by identifying protein expression in individual B cell 
populations. Additionally, our approach has revealed multiple, Pax5 containing B cell 
populations regardless whether the mechanism resulting in these patterns is a 
consequence of alternative splicing or stage specific protein-protein interactions.
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Therefore, our flow-cytometric technique has promising medical applications when 
assessing B cell populations in malignancies such lymphomas and myelomas.
Two-color flow and three-color cytometry is limited in its ability to identify all 
Pax5 isoforms. At this time, we have developed an approach to identify which specific 
Pax5 domains are present, but we still lack information for the Pax5 domains for which 
we do not possess antibodies, including the highly complex exon 7-9 region which 
undergoes extensive alternative splicing in humans, mouse, and trout [9, 12]. Therefore, 
we are still currently unable to determine if only one isoform is expressed per B cell 
population, or if multiple isoforms are expressed within a given population. However, 
one key advantage o f our approach is that we may use the current antibodies to detect if 
the paired domain, exon 6 and exon 10 regions are absent from a B cell population. Thus, 
we are still able to gamer important information on how key Pax5 domains are expressed 
and potentially used during B cell development and activation.
4.9 Future studies.
The primary goal o f future studies will be to verify the presence of Pax5 isoforms 
in the populations revealed by flow cytometry. One obvious experiment is to transfect 
Pax5 isoforms isolated by RT-PCR into 293T cell lines and demonstrate that the flow 
cytometric patterns for these cells are similar to those identified in this study. However, 
this approach may not work, as the same caveat of interfering protein-protein interaction 
would persist. An alternative approach would be to separate early developing murine B 
cells via cell surface markers (not available for trout) and use RT-PCR to demonstrate
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that isoforms containing the Pax5 C-terminus, but not paired domain, are more prevalent 
in these cells than in later developing stages. Although this experiment examines Pax5 at 
the RNA level and therefore may accurately demonstrate protein levels, it could still 
provide evidence that particular Pax5 isoforms are more present in any particular B cell 
developmental stage.
A second goal for future directions is to further characterize the unknown Pax5 
expressing, IgM negative population in trout spleen. It has been postulated that this 
population is composed of non-conventional B cell types, such as phagocytic B cells or 
B-l cells. One method to test this hypothesis is to culture trout immune cells in the 
presence o f fluorescent beads and use two-color flow cytometry to identify if phagocytic 
cells are Pax5 positive and IgM negative. If our hypothesis is correct, we would predict 
that a subset of phagocytic B cells is present in trout spleen that are lacking in HCmu but 
positive for full length Pax5 expression.
Conclusion.
B cell development and activation are complex, dynamic, and remarkably 
conserved processes in vertebrates. The use o f serological reagents and surface markers 
in mammalian models has enhanced our understanding of these processes by enabling us 
to demarcate distinct stages o f the developmental pathway. Only recently has research 
opened our eyes to the unique implementation o f adaptive immunity in teleosts. We now 
know that despite lacking the traditional primary immune organ, the bone marrow, 
teleosts follow a developmental pathway comparable to their mammalian counterparts.
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They share similar B cell stages, secondary immune locations, and most importantly, 
expression of Pax5 isoforms.
Using our flow cytometric approach, we have discovered that isoform expression 
changes during B cell development and activation stages, and potentially begins at an 
earlier stage than previously assumed. By better understanding these complex 
developmental pathways, we open future avenues to characterizing immune system 
malignancies and furthermore, provide an approach to analyze aberrant molecular 
expression. We also pose important evolutionary questions. It is fascinating that teleosts 
and mammals share similar early developing B cell populations lacking in Pax5 paired 
domain expression and furthermore express these developing B cell populations in 
similar secondary immune tissues. How these similarities in Pax5 isoform expression 
evolved and where they diverge remain elusive. However, by identifying Pax5 isoforms 
in individual developing and activated B cell populations, our research brings us one step 
closer to understanding their biological validity and function in humoral immunity.
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